Compositions and methods for ameliorating sexual sensitivity disorders
The problem of sensory disorders in the anogenital area is solved by using a topical composition of perenzepine in the anogenital area, significantly improving sexual function and pain, and providing a safe and economical treatment plan.
Patent Information
- Application Number
- CN202380022993.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-16
- Filing Date
- 2023-01-12
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively address sensory disorders in the anogenital area of men and women, including hyposensitivity, hypersensitivity and pain, leading to sexual dysfunction, and existing treatments such as surgery and medications have side effects and high costs.
Using topical compositions containing piperenzepine, the formulation is permeable through the skin or mucosa, directly acting on the anogenital area, increasing sensitivity and reducing pain.
It significantly improved the subject's sexual sensation, reduced ejaculation delay and orgasm difficulties, relieved pain, and provided a safe, economical and effective treatment option, reducing systemic side effects.
Smart Images

Figure BDA0005003696940000431 
Figure BDA0005003696940000432
Abstract
Description
[0001] Incorporation by reference into the priority application
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 300,008, filed on January 16, 2022. The disclosures of the above-referenced applications are incorporated herein by reference in their entirety. Technical Field
[0003] The present disclosure generally relates to a method and topical composition for treating sensory problems associated with sexual function in a subject. Specifically, the present disclosure relates to a topical, transdermal or transmucosal formulation for improving anogenital sensory disturbances in a subject, wherein the formulation comprises perrenzepine. Background Art
[0004] The penis and vulva are highly sensitive organs in men and women, respectively, containing thousands of nerve endings. These nerve endings need to be properly stimulated to become aroused. When sensation is impaired, it is more difficult for men and women to achieve sexual desire, orgasm or ejaculate, and enjoy sexual activity. This impairment may be a sudden / acute change due to, for example, illness or injury, or a gradual / chronic change that occurs with age. This impairment may result in loss / hyposensitivity, hypersensitivity or pain, or other sensory problems or impairments, each of which can lead to inability to engage in intimate relationships, relationship strain, reduced sexual satisfaction for partners, and psychological harm to those affected.
[0005] There are many factors that can contribute to hyposensitivity, including poor circulation from poor cardiovascular health, glycosylation from systemic diseases such as diabetes (i.e. diabetic neuropathy) or high blood sugar levels, the effects of certain medications, or peripheral neuropathy from traumatic injury. Other health problems such as lupus erythematosus, multiple sclerosis, cancer and its treatment such as prostate cancer, vascular disease and its treatment such as statins, Peyronie's disease and other biological / chemical causes may also lead to hyposensitivity. In addition, factors such as aging, lack of exercise, obesity, drug and alcohol use, smoking, use of antidepressants, low testosterone levels, etc. are also believed to cause loss of sensation. In addition, organ damage may also lead to impaired sensation. For example, a man's penis sensation may be impaired due to repeated masturbation or circumcision (removal of the highly sensitive foreskin tissue).
[0006] Furthermore, among the major categories of male sexual dysfunction, delayed ejaculation (DE) can cause significant distress or relationship problems, yet it has received the least attention. Delayed ejaculation is associated with genital sensation problems and is a manifestation of ejaculatory dysfunction that ranges from varying delays in ejaculation latency to complete inability to ejaculate, including delayed ejaculation (DE), retrograde ejaculation (RE), anorgasmia, anorgasmia, and painful ejaculation.
[0007] Current treatments focus primarily on improving genital sensitivity by optimizing health conditions, such as weight loss and smoking cessation. For circumcised men, foreskin reconstruction options are available, but such surgeries have mixed results and may be associated with adverse side effects. Surgical revision procedures can be extremely risky and expensive, making them unaffordable for most men. Topically applied creams may also be used to increase penile sensitivity because they are easy to use and inexpensive compared to other treatment options. Examples of sensitizing creams are disclosed in U.S. Patent Nos. 9,821,021 and 9,833,488.
[0008] Improving blood flow to the penis can also enhance its function, improve symptoms of erectile dysfunction and enhance sexual arousal. There are several drugs that can improve blood flow, including PDE5 inhibitors such as sildenafil and tadalafil. U.S. Patent No. 5,439,938 discloses a method for treating men, which includes a compound that generates sufficient amounts of nitric oxide to induce penile erection. In addition, L-arginine, as a precursor of nitric oxide in the body, its injection can promote vasodilation and blood flow (see Morikawa et al., Stroke 1994; 25: 429-435). Local delivery of arginine to enhance penile blood flow is disclosed in U.S. Patent No. 7,914,814. However, increasing blood flow is not the same as improving sensation problems.
[0009] Diabetic neuropathy is a type of nerve disorder caused by diabetes. People with diabetes develop nerve damage over time in various parts of the body, and nerve problems can occur in every organ system, including the digestive tract, heart, and sex organs. About 60 to 70 percent of people with diabetes will develop some form of neuropathy, which can lead to peripheral neuropathy in the hands and feet and further cause changes in sexual response, such as the inability to get an erection or reach orgasm. Improving the sensitivity of the remaining nerves in people with neuropathy may enhance sensation, relieve symptoms of neuropathy, and greatly improve the patient's quality of life.
[0010] Hypersensitivity or hyperalgesia can cause pain. Many of the same things that cause hyposensitivity can also cause hypersensitivity.
[0011] For women, vulvodynia is a complex gynecological condition characterised by chronic pain localised to the vulva. It is a debilitating condition that may persist for many years, leading to physical disability, sexual dysfunction and psychological difficulties. Daily activities and quality of life may be significantly impaired, with many patients having difficulty walking or sitting for long periods of time, sensitivity to clothing touching the vaginal area, and mild to severe pain that is often described as burning, stinging or itching. Despite the difficulty in diagnosis, it is generally estimated that more than 15% of adult women in Western countries may experience vulvodynia at some point in their lifetime. It most commonly affects women of childbearing age.
[0012] The most common form of vulvar pain is vulvar vestibulitis. Women with vulvar vestibulitis typically experience pain in the vestibular area that only occurs when touch or pressure is applied. Characteristics of vulvar vestibulitis include pain, tenderness, vestibular erythema, itching, swelling, and urethritis. The pain may be described as sharp, burning, or raw. Generalized vulvar pain is characterized by diffuse pain and / or burning in the vulva, labia majora, labia minora, and / or vestibule areas. The pain may be constant or intermittent, and although it is not necessarily triggered by touch or pressure, contact with these areas may make symptoms worse.
[0013] The etiology of vulvar pain is unknown. However, it has been hypothesized that viral, fungal, and bacterial invasions, allergic reactions, neuropathic processes, and autoimmune responses may play a role. Irritation of the muscles that support the uterus, bladder, and rectum (pelvic floor muscles or levator ani myalgia) and the nerves to the vulvar tissue (called pudendal neuralgia) may contribute to the additional painful symptoms associated with vulvar pain.
[0014] Pudendal neuralgia (or chronic perineal pain) refers to chronic pain in the area of the pudendal nerve distribution, which includes the female vulva, labia majora, skin around the anus, and part of the pubic mound. The pudendal nerve also innervates the urethra and anal mucosa. Therefore, dysfunction of the pudendal nerve not only affects the sensory function of the perineal skin (including the vulva), but also affects urination and defecation functions. Symptoms may include a persistent urge to urinate or a foreign body sensation in the rectum. Although these symptoms are not directly classified as pain, they still significantly affect the patient's daily life.
[0015] Pelvic pain is also very common in men, with an estimated 1 in 9 men experiencing pain in the lower area between the pubic bone and coccyx (called the "perineal area"). The main sensory and muscle control nerve in the perineal area is the pudendal nerve. In addition, penile pain in men can affect the base, shaft, or head of the penis, or even the foreskin. The pain may be accompanied by itching, burning, or throbbing sensations. Penile pain can be caused by an accident or illness, and men of any age can be affected. The severity of the pain depends on the underlying disease or condition, and some causes of penile pain include Peyronie's disease, priapism (for example, caused by medications for erectile problems or medications for depression, blood clotting disorders, mental health disorders, blood disorders (such as leukemia or sickle cell anemia), alcohol or drug use, penile or spinal cord injuries, etc.), balanitis, phimosis and incarcerated phimosis, sexually transmitted diseases, penile injuries, certain cancers, and skin diseases (such as psoriasis).
[0016] Chronic pain is often difficult to treat because there can be multiple causes. The first line of therapy is usually to address suspected causes with medications to treat infections and discontinue use of irritants and medications that may be causing the problem. Oral antihistamines and tricyclic antidepressants, oral supplements such as calcium citrate, physical therapy, and dietary changes may provide some symptom relief. More invasive treatments include local injections of interferon, laser therapy, and surgery, but these options are costly and can be associated with complications such as hematomas, wound dehiscence, and uneven healing. Currently, there is no known cure for chronic pain syndromes. Summary of the invention
[0017] Some embodiments of the present disclosure provide an external composition for increasing the sensitivity of a subject's sexual organ, the composition comprising pirenzepine or a pharmaceutically acceptable salt thereof and an external carrier.
[0018] In some embodiments, the composition further comprises one or more pharmaceutically acceptable excipients.
[0019] One embodiment is a method of improving sexual dyssensuality in a subject by administering to the anogenitalia of the subject an effective amount of a composition comprising a therapeutically effective amount of pirenzepine or a pharmaceutically acceptable salt thereof. DETAILED DESCRIPTION
[0020] Although certain embodiments of the present disclosure are shown and described herein, it will be appreciated by those skilled in the art that these embodiments are provided as examples only. Now, those skilled in the art may make many changes, modifications and substitutions without departing from the present disclosure. A variety of alternatives may be adopted to implement. It is intended to encompass the methods and structures within the scope of the appended claims and their equivalents.
[0021] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs. All patents and publications mentioned herein are incorporated herein by reference.
[0022] In the specification and claims, the singular form "a", "an", and "the" include plural references unless the context clearly requires otherwise.
[0023] When ranges are used herein to describe physical properties (such as molecular weight) or chemical properties (such as chemical formula), all combinations and subcombinations of ranges and specific embodiments are intended to be included. The term "approximately" when referring to a value or a range of values means that the value or range of values is approximate within the experimental error range (or within the statistical experimental error range), and therefore the value or range of values may vary between 1% and 15% of the value or range of values. The term "comprising" (and related terms such as "including" or "having" or "including") encompasses embodiments that are "consisting of" or "consisting essentially of", such as embodiments of any composition of matter, composition, method or process, etc.
[0024] Abbreviations used herein have their conventional meanings in chemistry and biology.
[0025] As used herein, the term "subject" or "patient" refers to any target of administration. The subject can be a vertebrate, such as a mammal. Thus, the subject can be a human. The term does not refer to a particular age or sex. Thus, adult, adolescent, and neonatal subjects, both male and female, are included. A patient refers to a subject suffering from a disease or disorder. The term "patient" includes human and veterinary subjects.
[0026] As used herein, the term "anogenital region" or "anogenital" refers to the area of the anus and genitals. In certain embodiments, the female anogenital region includes the external genitalia, cervix, vagina, vulva and vulvar skin, labia, vaginal introitus, clitoris, urethral orifice, urethral folds, vulvar vestibule, perineum and / or anus. In certain embodiments, the male anogenital region includes the penis, base of the penis, foreskin, urethral orifice, scrotum, perineum and anus. As used herein, the term "urogenital region" refers to the area of the distal urinary tract and genitals. In some subjects, the anogenital and / or urogenital regions may be ambiguous, intersex, or are transitioning from male to female or vice versa due to iatrogenic (e.g., surgery or hormone therapy) or natural / genetic reasons.
[0027] As used herein, the terms "treat," "treat," "cure," or "ameliorate," "improve," and "enhance" are used interchangeably. These terms refer to methods of obtaining beneficial or desired results, including but not limited to therapeutic benefit and / or prophylactic benefit. Therapeutic benefit is achieved by eliminating or alleviating the underlying disease being treated. In addition, improvement in a patient may be observed even if the patient still suffers from the underlying disease by eliminating or alleviating one or more physiological symptoms associated with the underlying disease. These terms also refer to restoring lost function or sensation. For prophylactic benefit, the composition may be given to a patient at risk for developing a particular disease, or to a patient having one or more physiological symptoms of a disease even if the disease has not been diagnosed. The composition may be given to a subject to prevent the progression of physiological symptoms or the underlying disease. For example, in the present disclosure, these terms refer to preventing and / or reversing sensory disturbances / problems associated with a subject's sexual function, or more specifically, to interruptions in a subject's anogenital sensory function. This includes biological improvements, such as reversing, preventing or slowing down neurodegeneration; functional symptom improvements, such as reversing, preventing or slowing down ejaculation dysfunctions ranging from low sensitivity, high sensitivity, various degrees of delayed ejaculation latency to complete inability to ejaculate, including delayed ejaculation (DE), retrograde ejaculation (RE), asexuality, anorgasmia and painful ejaculation; and sexual function symptom improvements, such as reduced ability to become aroused or maintain arousal or intensity of arousal, reduced intensity or ability of orgasm or ejaculation, prolonged ejaculatory refractory period; or improvements to normal sexual life, including unperceived or potential sexual function changes that occur with age. In one embodiment, the present disclosure contemplates the use of the disclosed formulations on other erogenous zones, such as nipples.
[0028] The term "therapeutic effect" as used herein includes the above-mentioned therapeutic benefits and / or preventive benefits. Preventive effects include delaying or eliminating the appearance of a disease or condition, delaying or eliminating the appearance of symptoms of a disease or condition, slowing, stopping or reversing the progression of a disease or condition, or any combination thereof, such as preventing and / or reversing peripheral neuropathy, or improving one or more sexual functions or sexual dysfunctions.
[0029] As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount of a compound described herein sufficient to affect the intended application, including but not limited to disease treatment, as defined below. The therapeutically effective amount may vary depending on the intended application (in vitro or in vivo), a reasonable benefit / risk ratio applicable to any medical treatment, the severity of the disease condition, the mode of administration, the subject being treated and the disease condition (e.g., the subject's weight and age, etc.), which can be readily determined by a skilled technician. The specific dosage will depend on the specific compound selected, the dosing regimen to be followed, whether it is co-administered with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system that carries it.
[0030] The term "pharmaceutically acceptable salt" as used herein refers to salts suitable for pharmaceutical use, particularly when used in the tissues of humans and lower animals, without causing adverse reactions such as excessive irritation, allergic reactions, etc. Pharmaceutically acceptable salts of amines, carboxylic acids and other types of compounds are well known in the art. For example, SM Berge et al. described pharmaceutically acceptable salts in detail in the Journal of Pharmaceutical Sciences 66: 1-19 (1977), which has been incorporated herein by reference. These salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately prepared by reacting free bases or free acidic functions with appropriate reagents, as described below. For example, the free base function can be reacted with an appropriate acid. In addition, if the compound of the invention carries an acidic group, its pharmaceutically acceptable salt can include metal salts, such as alkali metal salts, such as sodium salts or potassium salts; and alkaline earth metal salts, such as calcium salts or magnesium salts. Pharmaceutically acceptable non-toxic acid addition salts include salts of amino groups formed with inorganic acids (such as hydrochloric acid, bromic acid, phosphoric acid, sulfuric acid and perchloric acid) or organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts also include fatty acid salts, alginates, ascorbic acid salts, aspartates, benzoates, sulfates, succinates, maleates, formates, fumarates, citrates, lysine salts, thiocyanates, p-toluenesulfonates, undecanoates, valerates, etc. Representative alkali metal or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Further pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed when appropriate, including direct reaction with drug carboxylic acids or using halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, sulfonates and arylsulfonates and other para-ion pairing.
[0031] Pharmacological agents can be made into pharmaceutical compositions by combining with appropriate pharmaceutically acceptable carriers. The so-called "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" refers to a component, such as a carrier, a diluent, an excipient, a solvent, a synergist, etc., which is compatible with the pharmaceutical composition of one or more pharmacological agents and other optional ingredients, and even if combined with a pharmacological agent (e.g., piramuprazole), the biological or therapeutically effective activity of one or more pharmacological agents will not be eliminated, and it is suitable for the subject provided herein without causing inappropriate adverse side effects (such as toxicity, irritation, allergic reactions, and death). When the risk of side effects exceeds the benefits provided by the drug dose, these side effects are "inappropriate". Supplements or other active ingredients can also be incorporated into the composition.
[0032] As used herein, the terms "co-administration", "co-administration with", and grammatical equivalents thereof, include administering two or more agents to an animal simultaneously so that both agents and / or their metabolites are present in the animal simultaneously. Co-administration includes simultaneous administration in separate compositions, administration in separate compositions at different time points, or simultaneous administration in the same composition.
[0033] As used herein, "topical treatment" refers to treatment of a subject's anogenital sensory disturbances, wherein the drug is delivered by a local route, rather than by systemic delivery. This may include many different local areas or a few different local areas in skin treatments, wherein the drug may be applied to many different locations on the skin or a few different locations and delivered by skin absorption into the skin and adjacent tissues.
[0034] As used herein, "topical administration" refers to bringing a drug compound to the treatment site. For example, the formulation is applied directly to the skin area to be treated, sprayed onto the skin area to be treated, injected into the vagina or anal passage using a suppository or tampon, or applied to the skin of the anogenital area (e.g., penis, vulva, or anus) using wipes, pads / patches.
[0035] As used herein, "local tissue concentration" refers to the concentration of piramiprazol in the area of tissue involved in the treatment into which the therapeutic treatment has been delivered and absorbed.
[0036] The present disclosure provides compositions and methods for treating anogenital sensory disorders. In one embodiment, the present disclosure provides compositions and methods for improving anogenital sensitivity. In another embodiment, the present disclosure provides compositions and methods for treating anogenital hypersensitivity in a subject, including treating chronic vulvar and perineal pain, chronic pelvic floor and penile pain, and symptoms and conditions associated with such pain. Specifically, provided herein is a composition containing piramiprazole, wherein the composition is formulated for topical, transdermal or transmucosal administration.
[0037] The methods and compositions of the present disclosure are suitable for treating various conditions and symptoms associated with disturbances in normal anogenital sensation, including but not limited to anogenital hyposensitivity or hypersensitivity, penile numbness, delayed ejaculation or orgasm, vulvar numbness or hyposensitivity, or conversely, vulvar pain, sciatica, pelvic floor muscle tension myalgia, and pain associated with any of these conditions or symptoms. Vulvar pain may be localized or generalized vulvar pain. The condition may be selected from vaginal vestibulitis, localized triggered vestibulitis (LPV), tactile disorganized vulvar pain, vulvar dermatosis, or cyclical vulvovaginitis, etc. In one embodiment, the methods and compositions described herein are useful for treating delayed ejaculation disorders caused by sensory problems, particularly delayed ejaculation (DE), inability to ejaculate, anorgasmia, and painful ejaculation.
[0038] Piramuprazole is an M1 selective antagonist used to treat peptic ulcers because it reduces gastric acid secretion and reduces muscle spasms. It belongs to the class of drugs known as myocholinergic receptor antagonists - acetylcholine is a neurotransmitter of the parasympathetic nervous system that initiates a rest and digest state (rather than a fight or flight state), resulting in increased gastric motility and digestion; while piramuprazole will inhibit these effects, resulting in slower gastric motility, delayed gastric emptying and constipation. It has no effect on the brain and spinal cord because it cannot cross the blood-brain barrier. Piramuprazole has been studied for myopia control. It is currently being studied for the treatment of peripheral neuropathy (see WIPO patent application WO / 2012 / 055018A1 "Therapeutic composition for the treatment of diabetic symmetrical polyneuropathy", WIPO patent application WO / 2015 / 089664A1 "Methods and compositions for the treatment of peripheral neuropathy" and WO / 2020 / 198252A1 "Topical preparations for peripheral neuropathy", each of which has been incorporated by reference).
[0039] "Pharmaceutically acceptable salts" herein refer to salts that are suitable for contact with human or animal tissues without undue toxicity, irritation or allergic response, etc., within the scope of medical judgment, and provide a reasonable benefit / risk ratio. "Pharmaceutically acceptable salts" refer to salts or esters of any at least substantially non-toxic compound disclosed herein, which, after administration to a recipient, can directly or indirectly provide a compound disclosed herein or its metabolites or residues with inhibitory activity.
[0040] Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in detail by SM Berge et al. in the Journal of Pharmaceutical Sciences, Vol. 66, 1977, pp. 1-19, the contents of which have been incorporated by reference. Pharmaceutically acceptable salts of the compounds disclosed herein include salts derived from appropriate inorganic and organic acids, including the free base of pilamprazole or pilamprazole monohydrate. Examples of pharmaceutically acceptable non-toxic acid addition salts include amino salts formed with mineral acids such as hydrochloric acid (e.g., pilamprazole dihydrochloride or monohydrochloride), bromic acid, phosphoric acid, sulfuric acid, and perchloric acid, or organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or salts formed by other methods in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, disulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, lauryl sulfate, acrylate, malonate, lactate, laurate, lauryl sulfate, malate, maleate, maleonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, citrusate, tetrahydrothiopheneate, 3-phenylpropionate, phosphate, pyromycinate, valerate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, and the like.
[0041] Formulas as described herein are suitable for topical treatment of subject's anogenital sensory disorders. These formulas include piramuprazole and are formulated as compositions suitable for topical administration to a subject. These compositions may include gels, creams, lotions, solutions, suspensions, emulsions, ointments, powders, crystalline forms, sprays, foams, pastes, plasters, paints, bioadhesives, suppositories, sanitary napkins, wound dressings, skin patches, reproductive pads, transdermal patches, etc. These formulas may also include additional ingredients, such as for promoting active compound delivery, enhancing therapeutic effects, having secondary effects or reducing side effects. These formulas allow piramuprazole to be effectively delivered to the administration site, such as but not limited to penis, vagina and tissues and organs around them.
[0042] The topical formulation can be formulated in the form of a gel, lotion, cream, mousse, aerosol, ointment or lubricant, as long as the formulation can remain substantially in place when applied, especially when applied to the genitals. For example, there will be no substantial loss within a sufficient time after application to enable an individual to apply the formulation to relevant parts of the penis, including the glans of the penis, or to relevant parts of the vagina, including the vulva. The formulation can also be formulated to dry relatively quickly and penetrate the subject's skin. Other factors to consider include transmission (or non-transmission) to sexual partners, the ability to clean any residual formulation, and the chronic effects of the formulation in repeated use.
[0043] In certain embodiments, the topical formulations provided herein may include a pharmaceutical carrier, a diluent, a cosolvent, an emulsifier, a penetration enhancer, a preservative, an emollient, or a combination thereof. Acceptable carriers or diluents for treatment are well known in the pharmaceutical arts and are described, for example, in Florence AT and Siepmann J, eds. Modern Pharmacy Volume 1: Basic Principles and Systems 5th ed. CRC Press, 2009; Augsburger LL and Hoag SW, eds. Pharmaceutical Dosage Forms: Tablets 3rd ed. CRC Press, 2016; Ansel HC. Introduction to Dosage Forms 2nd ed. Lea & Febiger, 1976; Adejare A, ed. Remington's Science and Practice of Pharmacy 23rd ed. Academic Press, 2020; Brunton L et al., eds. Goodman & Gilman's Fundamentals of Pharmacology 13th ed. McGraw-Hill, 2017; Shah VP et al., eds. Topical Drug Bioavailability, Bioequivalence, and Permeation 2nd ed. Springer, 2015; Hillery AM and Park K. Drug Delivery and Targeting: For Pharmacists and Pharmacists. CRC Press, 2016; Allen L. Dosage Forms and Drug Delivery Systems 11th ed. LWW Press, 2017 (all references are incorporated herein by reference).
[0044] Excipients
[0045] Pharmaceutical compositions may include one or more inert excipients, including water, buffered aqueous solutions, surfactants, volatile liquids, starches, polyols, granulating agents, microcrystalline cellulose, diluents, lubricants, acids, bases, salts, emulsifiers such as oil-in-water emulsions, oils such as mineral oils and vegetable oils, moisturizers, chelating agents, antioxidants, sterile solutions, complexing agents, disintegrants, etc. The CTFA Cosmetic Ingredient Handbook, Eighth Edition, 2000 and Tenth Edition, 2004, which are incorporated herein by reference in their entirety, describe cosmetic and pharmaceutical ingredients widely used in skin care formulations and are suitable for use in the formulations of the present disclosure. Examples of these functional classes disclosed in this reference include absorbents, abrasives, anti-caking agents, anti-foaming agents, antimicrobial agents, antioxidants, binders, biological additives, buffers, fillers, chelating agents, chemical additives, pigments, cosmetic astringents, cosmetic biocides, denaturants, pharmaceutical astringents, topical anesthetics, film formers, fragrance ingredients, humectants, emulsifiers, sunscreens, pH adjusters, plasticizers, preservatives, reducing agents, skin bleaching agents, skin conditioning agents (emulsifiers, humectants, miscellaneous and occlusive), skin protectants, solvents, foam enhancers, water-soluble and water-insoluble solubilizers, steroidal anti-inflammatory drugs, surfactants / emulsifiers, suspending agents (non-surfactant), sunscreens, local anesthetics, UV absorbers, SPF enhancers, thickeners, water-proofing agents and viscosity increasing agents (water-soluble and water-insoluble).
[0046] Surfactants that can be used to form pharmaceutical compositions and dosage forms include, but are not limited to, hydrophilic surfactants, lipophilic surfactants, and mixtures thereof. That is, a mixture of hydrophilic surfactants can be used, a mixture of lipophilic surfactants can be used, and a mixture of at least one hydrophilic surfactant and at least one lipophilic surfactant can also be used.
[0047] One of the surfactants may be in the form of a sodium salt of the compound, possibly including a monosodium salt. Suitable sodium salt surfactants may be selected based on desirable properties, including high polymerization rate, small particle size suitable for delivery, good polymerization yield, stability (including freeze-thaw stability and shelf life stability), improved surface tension properties, and lubricity.
[0048] The surfactant may be any suitable, non-toxic compound that is non-reactive with the drug and that significantly reduces the surface tension between the drug, the excipients, and the site of administration. Such surfactants include, but are not limited to, oleic acid, available under the trademarks Mednique 6322 and Emersol 6321 (from Cognis Corp., Cincinnati, Ohio); cetylpyridinium hydrochloride (from Arrow Chemical, Inc., Westwood, NJ); soy lecithin, available under the trademark Epikuron 200 (from Lucas Meyer, Decatur, Ill.); polyoxyethylene (20) sorbitan monolaurate, available under the trademark Tween 20 (from ICI Specialty Chemicals, Wilmington, Del.); polyoxyethylene (20) sorbitan monostearate, available under the trademark Tween 60 (from ICI); polyoxyethylene (20) sorbitan monooleate, available under the trademark Tween 80 (from ICI); polyoxyethylene (10) stearyl alcohol ether, available under the trademark Brij 76 (from ICI); polyoxyethylene (2) oleic acid alcohol ether, available under the trademark Brij92 (from ICI); polyoxyethylene-polyoxypropylene-ethylenediamine block copolymer, available under the trademark Tetronic150R1 (from BASF); polyoxypropylene-polyoxyethylene block copolymer, available under the trademark Pluronic L-92, Pluronic L-121 and Pluronic F 68 (from BASF); castor oil ethoxylate, available under the trademark Alkasurf CO-40 (from Rhone-Poulenc, Mississauga, Ontario, Canada), and mixtures thereof.
[0049] Suitable hydrophilic surfactants generally have an HLB value of at least 10, while suitable hydrophobic surfactants generally have an HLB value of about 10 or less. An empirical parameter used to characterize the relative hydrophilicity and hydrophobicity of nonionic amphoteric compounds is the hydrophilic-hydrophobic balance ("HLB" value). Surfactants with lower HLB values are more lipophilic or hydrophobic, having greater solubility in oils, while surfactants with higher HLB values are more hydrophilic, having greater solubility in aqueous solutions. It is generally believed that hydrophilic surfactants are compounds having HLB values greater than about 10, as well as anionic, cationic or zwitterionic compounds, for which the HLB scale is generally not applicable. Similarly, hydrophobic (i.e., hydrophobic) surfactants are compounds having HLB values approximately equal to or less than about 10. However, the HLB value of a surfactant is only a rough guide that is generally used to facilitate industrial, pharmaceutical and cosmetic emulsion formulations.
[0050] The hydrophilic surfactant may be ionic or nonionic. Suitable ionic surfactants include, but are not limited to, alkyl ammonium salts; oxalic acid salts; fatty acid derivatives of amino acids, oligopeptides and polypeptides; glyceride derivatives of amino acids, oligopeptides and polypeptides; lecithin and hydrogenated lecithin; dissolved lecithin and hydrogenated dissolved lecithin; phospholipids and their derivatives; dissolved phospholipids and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium sulfate; acetylated tartaric acid monoesters and diesters of glycerol; succinic acid acylated monoesters and diesters of glycerol; citric acid monoesters and diesters of glycerol; and mixtures thereof.
[0051] In the above group, ionic surfactants include but are not limited to: lecithin, dissolved lecithin, phospholipids, dissolved phospholipids and their derivatives; carnitine fatty acid ester salts; alkyl sulfates; fatty acid salts; sodium sulfate; acetylated tartaric acid monoesters and diglycerides; succinic acid acylated monoesters and diglycerides; citric acid esters and diglycerides; and mixtures thereof.
[0052] The ionic surfactant can be an ionic form of lecithin, dissolved lecithin, phospholipids, dissolved phospholipids, phospholipids, phosphocholine, phosphoethanolamine, phosphoglycerol, phosphoric acid, phosphoserine, dissolved phosphocholine, dissolved phosphoethanolamine, dissolved phosphoglycerol, dissolved phosphoric acid and dissolved phosphoserine; PEG-phosphoethanolamine, PVP-phosphoethanolamine, fatty acid lactates, stearic acid-2-lactylate, stearoyl lactylate, succinic acid acylated monoglyceride, succinic acid acylated diglyceride, citrate monoglyceride, citrate diglyceride, cholestylarcosine, caproate, caprate, caprate, laurate, myristate, linolenate, linoleate, fatty acid salts, lauryl ether sulfate, hexadecyl sulfate, tartrate disuccinate, citrate esters, citrate esters and mixtures thereof.
[0053] The hydrophilic nonionic surfactant may include, but is not limited to, alkyl glucosides; alkyl maltosides; alkyl mercaptoglycosides; lauryl myrogol glycerides; polyoxyalkyl ethers, such as polyethylene glycol alkyl ethers; polyoxyalkyl phenols, such as polyethylene glycol alkyl phenols; polyoxyalkyl phenol fatty acid esters, such as polyethylene glycol fatty acid monoesters and polyethylene glycol fatty acid diesters; polyethylene glycol glycerol fatty acid esters; polyglycerol fatty acid esters; polyoxyalkyl sorbitan fatty acid esters, such as polyethylene glycol sorbitan fatty acid esters; hydroxypropyl trihydroxypropyl fatty acid esters; and mixtures thereof; polyethylene glycol sorbitan fatty acid esters and hydroxy fatty acid esters of polyoxyalkyl sorbitan fatty acid esters and polyethylene glycol sorbitan fatty acid esters.
[0054] Other hydrophilic nonionic surfactants include, but are not limited to, PEG-10 laurate, PEG-12 laurate, PEG-20 laurate, PEG-32 laurate, PEG-32 dilaurate, PEG-12 oleate, PEG-15 oleate, PEG-20 oleate, PEG-20 dioleate, PEG-32 oleate, PEG-200 oleate, PEG-400 oleate, PEG-15 stearate, PEG-32 distearate, PEG-40 stearate, PEG-100 stearate, PEG-20 dilaurate, PEG-25 glyceryl oleate trioleate, PEG-32 dioleate, PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-20 glyceryl stearate, PEG-20 glyceryl oleate, PEG-30 glyceryl oleate, PEG-30 glyceryl laurate, PEG-40 Glyceryl laurate, PEG-40 palm kernel oil, PEG-50 hydrogenated castor oil, PEG-40 castor oil, PEG-35 castor oil, PEG-60 castor oil, PEG-40 hydrogenated castor oil, PEG-60 hydrogenated castor oil, PEG-60 corn oil, PEG-6 capric / caprylic glycerides, PEG-8 capric / caprylic glycerides, polyglyceryl-10 laurate, PEG-30 cholesterol, PEG-25 phytosterols, PEG -30 soybean sterol, PEG-20 oleic trioleate, PEG-40 sorbitan oleate, PEG-80 sorbitan stearate, polysorbate-20, polysorbate-80, POE-9 lauryl ether, POE-23 lauryl ether, POE-10 oleyl ether, POE-20 oleyl ether, POE-20 stearyl ether, tocopherol PEG-100 succinate, PEG-24 cholesterol, polyglyceryl-10 oleate, Tween 40, Tween 60, sucrose monostearate, sucrose monolaurate, sucrose monopalmitate, PEG 10-100 nonylphenol series, PEG 15-100 octylphenol series and polyoxyethylene.
[0055] Suitable lipophilic surfactants include, for example, fatty alcohols; glycerol fatty acid esters; acetylated glycerol fatty acid esters; lower alcohol fatty acid esters; propylene glycol fatty acid esters; sorbitol fatty acid esters; polyethylene glycol sorbitol fatty acid esters; sterols and sterol derivatives; polyoxyethylated sterols and sterol derivatives; polyethylene glycol alkyl ethers; sugar esters; sugar ethers; mono- and diglycerol lactic acid derivatives; polyoxyethylated polyester polyethanol, vegetable oil, hydrogenated vegetable oil, fatty acid and hydroxy fatty acid esters of one of sterols; oil-soluble vitamins / vitamin derivatives; and mixtures thereof. In these groups, the lipophilic surfactant includes glycerol fatty acid esters, propylene glycol fatty acid esters and mixtures thereof, or hydrophobic fatty acid esters of at least one of polyols and vegetable oil, hydrogenated vegetable oil and glyceride.
[0056] Surfactants can be used in any formulation described herein, wherein their use is not otherwise limited. In certain embodiments of the invention, it is desirable to use no surfactant or a limited class of surfactants. Topical formulations according to the present disclosure may be surfactant-free, or contain relatively little surfactant, i.e., contain no more than about 0.0001% surfactant by weight of the total formulation. In particular, this is true if clenbuterol as described above is used. However, if desired, the formulation may contain surfactants commonly used in topical formulations, such as oleic acid, lecithin, sorbic acid trioleate, cetylpyridinium chloride, benzalkonium salt, polyoxyethylene (20) sorbic acid monoester, polyoxyethylene (20) sorbic acid monostearate, polyoxyethylene (20) sorbic acid monooleate, polyoxypropylene / polyoxyethylene block copolymers, polyoxypropylene / polyoxyethylene / ethylenediamine block copolymers, ethoxylated castor oil, etc., wherein the content of the surfactant (if present) may be about 0.0001 to 1% by weight of the total formulation, in particular about 0.001 to 0.1% by weight of the total formulation. Other suitable surfactants / emulsifiers are well known to the skilled artisan and are listed in the CTFA International Cosmetic Ingredient Dictionary and Handbook, Vol. 2, 7th Edition (1997).
[0057] Other suitable aqueous carriers include, but are not limited to, Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl pyrrolidone and dragon glue, and wetting agents such as lecithin. Preservatives suitable for aqueous suspensions include ethyl paraben and n-propyl paraben.
[0058] Chelating agents used to prepare pharmaceutical compositions and dosage forms include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), disodium EDTA, disodium calcium diacetate, trisodium EDTA, albumin, transferrin, deferoxamine, deferoxamine, deferoxamine mesylate, tetrasodium EDTA and dipotassium EDTA, sodium silicate, or any combination thereof. In certain embodiments, up to about 0.1% weight / volume of a chelating agent, such as EDTA or a salt thereof, may be added to the formulations of the present disclosure.
[0059] Preservatives used to prepare pharmaceutical compositions and dosage forms of the present disclosure include, but are not limited to, purite, peroxide, perborate, imidazolidinyl urea, diimidazole lignourea, phenoxyethanol, benzyl ammonium chloride including benzalkonium salt, methyl paraben, ethyl paraben and propyl paraben. In other embodiments, the applicable preservatives of the composition include: benzalkonium salt, purite, peroxide, perborate, thiomercuric, chlorobutanol, methyl paraben, propyl paraben, phenethyl alcohol, diethylene glycol, sorbic acid, Onamer M or other agents known to the technician. In certain embodiments, these preservatives can be used at a level of about 0.004% to 0.02% weight / volume. In certain compositions of the present application, for example, preservatives, such as benzalkonium salt, methyl paraben and / or propyl paraben, can be used at about 0.001% to at least about 0.01%, such as about 0.005% weight / volume. It has been found that a concentration of about 0.005% benzalkonium salt may be sufficient to protect the disclosed compositions from attack by microorganisms. The skilled person can determine the appropriate concentrations of the ingredients and the combination of the various ingredients that produce the appropriate topical formulation. For example, eye drops or formulations for use on the skin may use a mixture of methylparaben and propylparaben at about 0.02% and about 0.04% weight / volume, respectively. In certain embodiments, the amount of methylparaben and / or propylparaben used in these formulations may be up to about 0.02% weight / volume and about 0.04% weight / volume, respectively, including embodiments in which no methylparaben or no propylparaben is used.
[0060] Lubricants used to prepare pharmaceutical compositions and dosage forms include, but are not limited to, calcium stearate, magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol, polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc, hydrogenated vegetable oils (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil, and soybean oil), zinc stearate, ethyl acetate, ethyl laurate, agar, or mixtures thereof.
[0061] Thickeners useful in preparing pharmaceutical compositions and dosage forms include, but are not limited to, isopropyl isopropyl creatine, isopropyl isopropyl palmitate, dodecyl neopentanoate, squalane, mineral oil, C12-C15 benzoates, and hydrogenated polyisobutene. Thickeners that do not disrupt other compounds in the final product, such as nonionic thickeners, may be desirable. Selection of other thickeners is within the skill in the art.
[0062] Skin conditioning agents can be emollients, moisturizers and wetting agents. Moisturizers are moisturizers that promote water retention due to their hygroscopic properties. Suitable skin conditioning agents include urea; guanidine; aloe; glycolic acid and glycolate salts, such as ammonium salts and quaternary ammonium salts; lactic acid and lactate salts, such as sodium lactate, ammonium lactate and quaternary ammonium lactate; polyhydroxy alcohols, such as sorbitol, glycerol, mannitol, xylitol, hexatriol, propylene glycol, butylene glycol, hexylene glycol, polymeric ethylene glycol and polypropylene glycol; carbohydrates, such as alkoxy glucose; starch; starch derivatives; glycerol; pyrrolidinedionecarboxylic acid (PCA); lactamide monoethanolamine; acetamide monoethanolamine; volatile silicone oil; non-volatile silicone oil; and mixtures thereof. Suitable silicone oils can be polydialkylsiloxanes, polydiarylsiloxanes, polyalkylarylsiloxanes and cyclosilanes containing 3 to 9 silicon atoms.
[0063] Emollient is a kind of oily or oily substance, helps to smooth and soften the skin, and may reduce its roughness, cracking or stimulation.Typical applicable emollients include mineral oil, lanolin oil, coconut oil, cocoa butter, olive oil, almond oil, macadamia oil, such as aloe extract, synthetic jojoba oil, natural Sonora jojoba oil, safflower seed oil, corn oil, liquid lanolin, cottonseed oil and peanut oil with viscosity in the range of 50 to 500 centipa seconds (cps).In certain embodiments, emollient is a mixture of mono, di and triglyceride of cocoa butter, sold with the Myritol 331 trademark of Henkel KGaA, or the lauryl ether sold with the Cetiol OE trademark of Henkel KGaA, or the C12-C15 alkyl benzoate sold with the Finsolv TN trademark of Finetex. Another suitable emollient is silicone fluid DC200Fluid350 from Dow Corning Corp., as well as caprylic acid, one of the fatty acids found in coconut oil, which is believed to have strong antibacterial, antifungal and anti-inflammatory properties.
[0064] Other suitable emollients include squalane, castor oil, polybutene, sweet almond oil, avocado oil, torreya oil, castor oil, vitamin E acetate, olive oil, silicone oils such as dimethicone and cyclosilane, linoleyl alcohol, oleyl alcohol, cereal germ oils such as wheat germ oil, isopropyl isopropionate, isopropyl caprylate, creatine isopropionate, hexyl stearate, butyl stearate, decyl oleate, acetylated glycerides, caprylic and benzoic acid esters of (C12-C15) alcohols, caprylic and capric esters of alcohols and polyols such as caprylic esters of ethylene glycol and glycerol, castor oil esters such as isopropyl adipate, hexyl laurate and octyl caprate, lauroyl maleate, hydrogenated vegetable oils, phenyl trimethicone, jojoba oil and aloe vera extract.
[0065] Other suitable emollients that are solid or semisolid at room temperature may also be used. Such solid or semisolid cosmetic emollients include glyceryl stearate, hydrogenated lanolin, hydroxylated lanolin, acetylated lanolin, paraffin, isopropyl isopropionate, isopropyl palmitate, hexadecanoate, butyl stearate, myristostearate, cottonseed alcohol, isononyl alcohol and isoheptyl lanolinate. One or more emollients may be selected in the formulation.
[0066] Antioxidants can be used to prepare pharmaceutical compositions and dosage forms, including, but not limited to, propyl, octyl, and dodecyl gallate, hydroxybenzoate (BHA, usually purchased as a mixture of ortho and meta isomers), green tea extract, uric acid, cysteine, pyruvate, 3,4-dihydroxyguar acid, ascorbic acid, ascorbate salts such as ascorbyl palmitate and sodium ascorbate, ascorbyl glucosamine, vitamin E (i.e., tocopherols such as alpha-tocopherol), vitamin E derivatives (e.g., tocopherol acetate), retinoids (e.g., retinoic acid, retinol, trans-retinol, cis-retinol, a mixture of trans- and cis-retinol, 3-dehydroretinol) and vitamin A derivatives (e.g., retinoic acid ethyl ester, retinal and retinoic acid palmitate, also known as tetramer palmitate), sodium citrate, sodium sulfite, lycopene, anthocyanidins, bioflavonoids (e.g., hesperidin, tartrate, rutin and quercetin), superoxide dismutase, glutathione peroxidase, hydroxybenzoic acid (BHT), indole-3-methylpropenol, genistein, melatonin, thioisothiocyanates, progesterone, lipoic acid and 4-hydroxy-5-methyl-3[2H]-furanone.
[0067] Skin protectants are agents that protect the skin from chemical irritants and / or physical irritants, such as ultraviolet rays, and include sunscreens, anti-acne additives, anti-wrinkle and anti-skin atrophy agents. Suitable sunscreens as skin protectants include 2-ethylhexyl p-methoxycinnamate, 2-ethylhexyl N,N-dimethyl-p-aminobenzoate, p-aminobenzoic acid, 2-phenylbenzimidazolin-5-sulfonic acid, octyl methyl salicylate, isooctyl benzoate, 4,4′-methoxy-t-butyldibenzoylmethane, 4-isopropyl benzophenone, 3-benzylidene vanillone, 3-(4-methylbenzylidene) vanillone, atamyl, ultrafine titanium dioxide, zinc oxide, Iron oxide, silica, 4-N,N-(2-ethylhexyl) methylaminobenzoate with 2,4-dihydroxybenzophenone, 4-N,N-(2-ethylhexyl)-methylaminobenzoate with 4-hydroxydibenzoylmethane, 4-N,N-(2-ethylhexyl)-methylaminobenzoate with 2-hydroxy-4-(2-hydroxyethoxy)benzophenone and 4-N,N-(2-ethylhexyl)-methylaminobenzoate with 4-(2-hydroxyethoxy)dibenzoylmethane. Suitable anti-acne agents include salicylic acid, 5-octanoyl salicylic acid, m-hydroxyphenol, vitamin A acid and its derivatives, sulfur-containing amino acids D and L, lipoic acid, antibiotics and antibacterial agents such as benzoyl peroxide, octylbiprofen, tetracycline, 2,4,4'-trichloro-2'-hydroxydiphenyl ether, 3,4,4'-trichlorobenzidine, white acid, phenoxyethanol, phenoxypropanol, phenoxyisopropanol, ethyl acetate, clindamycin and minocycline, flavonoids and bile salts such as tuna sulfate, deoxycholic acid and cholic acid. Examples of anti-wrinkle and anti-skin atrophy agents include vitamin A acid and its derivatives, retinol, retinyl esters, salicylic acid and its derivatives, sulfur-containing amino acids D and L without cysteine, α-hydroxy acids (such as acetic acid and lactic acid), phytic acid, lipoic acid, and phosphatidic acid.
[0068] Irritation-reducing additives are used to minimize or eliminate the possibility of skin irritation or damage caused by the permeation-enhancing base, drying agent or other ingredients. Suitable irritation-reducing additives include, for example: alpha-tocopherol; monoamine oxidase inhibitors, particularly phenyl alcohols such as 2-phenyl-1-ethanol; glycerol; salicylic acid and its salts; ascorbic acid and its salts; ionophores such as monensin; amphoteric amines; ammonium chloride; N-acetylcysteine; cis-uric acid; capsaicin; and chloroquine. If present, irritation-reducing additives can be added to the formulation at an effective concentration to reduce irritation or skin damage, typically not more than about 20% by weight, more typically not more than about 5% by weight.
[0069] A dry feel improver is an agent that, when added to an emulsion, imparts a "dry feel" to the skin when the emulsion dries. Dry feel improvers may include talc, kaolin, chalk, zinc oxide, silicone oil, inorganic salts such as barium sulfate, surface treated silica, precipitated silica, fumed silica such as Aerosil from Degussa, etc. Another dry feel improver is epichlorohydrin cross-linked glycerol starch, of the type disclosed in US Pat. No. 6,488,916 to Degussa, New York, USA.
[0070] In certain embodiments, the compositions according to the present invention are formulated to have a viscosity that is most suitable for the target tissue (e.g., the perineum) and to simulate the properties of normal reproductive fluids. For example, a composition formulated as a gel for application to a mucous membrane may be designed to have a viscosity value consistent with or similar to normal mucus and exhibit non-Newtonian, shear-thinning (pseudoplastic) flow properties. Similar processes are used to evaluate, for example, quantify and compare viscosity properties with products on the market.
[0071] Formulations for use on the skin (e.g., vulva, perineum, or penis) or inside the vagina may have a viscosity enhancer added so that they are easily spread to form a thin layer when minimal physical pressure is applied, and have sufficient viscosity and shear thinning properties so that the formulation does not "bleed" or flow out of the reproductive tissue when applied topically. Adhesive formulations that have adhesion that remains on reproductive surfaces (e.g., vulva, vagina, penis, foreskin surfaces) to prolong biological activity are known in the literature (reviewed by Khutoryanskiy, Macromol. Biosci. 11:748, 2011; Brooks, Front. Chem. 3:65, 2015). Adhesive formulations must have a polymer composition that can actively mix and interact with physiological mucus and mucus of secretions. Some common gels cannot interweave with natural mucus and therefore are not adhesive and are quickly lost from the epithelium.
[0072] Compositions disclosed herein may include a viscosity enhancer, and its content range may be about 0.05% to about 10% of the formula weight. In certain embodiments, the viscosity enhancer includes surfactant cellulose or gum. Surfactant cellulose and gum may also play an emulsifying effect, and particles and essential oils are pulled into solution. In certain embodiments, additional surfactants harmful to cells are not required or included. In certain embodiments, the viscosity enhancer includes guar gum, methylcellulose, ethylcellulose, ethylmethylcellulose, ethylhydroxyethylcellulose, carboxymethylcellulose, hydroxypropylcellulose, hydroxyethylmethylcellulose, hydroxypropylmethylcellulose (hydroxymethylcellulose), hydroxyethylcellulose, dodecylhydroxyethylcellulose, hydroxypropyl guar gum, glycosaminoglycans (e.g. hyaluronic acid), nonionic triblock copolymers such as polyoxyethylene-polypropoxyethylene-polyoxyethylene (poloxamers), gelatin, alginate, agar and any combination. In certain embodiments, the composition may include glycosaminoglycans (eg, hyaluronic acid) containing viscosity increasing agents, nonionic triblock copolymers such as polyoxyethylene-polypropoxyethylene-polyoxyethylene (poloxamers), gelatin, agar, and combinations thereof.
[0073] In certain embodiments, the topical composition may further include a pH adjusting agent to adjust the final pH of the composition to a target or desired pH. The pH adjusting agent may include an acidifying agent, an alkalizing agent, and / or both an acidifying agent and an alkalizing agent. In certain embodiments, the pH adjusting agent is present in an amount ranging from about 0.01% to about 1%.
[0074] In certain embodiments, the topical compositions of the present disclosure may also include a buffer. The content of the buffer may range from about 0.01% to about 0.9% of the formula weight. A buffer refers to a compound or mixture that, when present in a solution, is able to resist changes in the pH of a solution when a small amount of acid or alkali is added to the solution or when diluted with a solvent or body fluid. Buffer capacity is a measure of the resistance of a solution to changes in its pH when an acid or alkali is added. The total amount of the buffer (e.g., a conjugate acid-base pair) is selected to keep the pH of the composition within a desired pH or pH range. Therefore, the greater the buffer capacity, the more resistant the pH of the composition is to changes in acid or alkali. In certain embodiments, the buffer comprises an acidic species to neutralize hydroxide (OH-) ions and an alkaline species to neutralize hydrogen (H+) ions. However, the acidic and alkaline species of the buffer should not be consumed by each other through a neutralization reaction.
[0075] In certain embodiments, the buffer is a simple buffer solution including a weak acid and a salt of the weak acid or a weak base and a salt of the weak base. Thus, the buffer may include a weak acid / weak acid salt pair or a weak base / weak base salt pair. For example, the pairing of weak acid / weak acid salt and weak base / weak base salt includes citric acid / sodium citrate, lactic acid / sodium lactate, acetic acid / sodium acetate, sodium phosphate monohydrate / sodium phosphate dihydrate, propionic acid / sodium propionate, butyric acid / sodium butyrate, carbonic acid / sodium bicarbonate, malic acid / sodium malate, ascorbic acid / sodium ascorbate, benzoic acid / sodium benzoate, succinic acid / sodium succinate, and boric acid / boric acid. In certain embodiments, the buffer includes unrelated weak acid-base pairs. Examples of such compositions include sodium phosphate dihydrate / citric acid, sodium phosphate dihydrate / lactic acid, sodium phosphate monohydrate / sodium lactate, sodium phosphate monohydrate / sodium citrate, sodium citrate / lactic acid, sodium lactate / citric acid, potassium hydrogen phosphate monohydrate / citric acid, potassium hydrogen phosphate monohydrate / lactic acid, potassium hydrogen phosphate monohydrate / sodium lactate, potassium hydrogen phosphate monohydrate / sodium citrate, potassium lactate / citric acid, and sodium lactate / citric acid. In addition, for polyvalent anions, calcium salts can be used instead of sodium salts (e.g., calcium citrate). Example buffers can also include gluconolactone / gluconic acid.
[0076] In certain embodiments, the buffer is selected to have a pKa of its acidic form that is the same or close to the pH required for the composition, or to have a similar buffering capacity within the required pH range to adapt to the surface and liquid (e.g., vaginal mucosal acid barrier, cervical-vaginal secretions, semen, menstrual flow, or a combination thereof) present physiologically in the perineum, or to maintain the pH to the pH of the target epithelial surface (e.g., Rastogi et al., Contraception, 93:337, 2016). In certain embodiments, the buffer includes a monocarboxylate, a dicarboxylate, a carboxylic acid, or a combination thereof. In certain embodiments, the buffer may include acetate, borate, citrate, fumarate, lactate, malate, malonate, maleate, nitrate, phosphate, propionate, succinate, tartrate, trimethylamine, or any combination thereof. In certain embodiments, the buffer comprises lactic acid, sodium lactate, sodium phosphate (monobasic, dibasic or both), potassium phosphate (monobasic, dibasic or both), sodium citrate, potassium citrate, calcium citrate, acetic acid, sodium acetate, citric acid, disodium citrate, boric acid / sodium, succinic acid, sodium succinate, gluconolactone, disodium citrate, tartaric acid, sodium tartrate, sodium ascorbate, ascorbic acid, trimethylamine (Tris), or any combination thereof. In certain embodiments, the buffer comprises citric acid and disodium phosphate, lactic acid and sodium lactate, gluconolactone, or a combination of mono- or di-phosphate and lactic acid.
[0077] In one embodiment, the topical composition of the present disclosure is particularly isotonic to the target genital body fluid or tissue it will contact. Tonicity is a measurement of the effective osmotic pressure gradient (defined by the water potential of the two solutions) of two solutions separated by a semipermeable membrane. Tonicity is often used to describe the response of cells immersed in an external solution. In other words, tonicity refers to the relative concentration of the solution, which determines the direction and extent of diffusion of fluid through the cell membrane in the tissue. Blood generally has an osmotic pressure corresponding to a 0.9% solution of sodium chloride (about 280 milliosm / kg). However, the osmotic pressure of physiological fluids in the perineum can vary from the low end of physiological fluid occurrence (e.g., cervical-vaginal fluid about 128 milliosm / kg) to about 280 milliosm / kg of menstrual blood, to higher levels of semen (e.g., about 320+ milliosm / kg). When the osmotic pressure of a composition (e.g., a solution or gel) matches the physiological fluid it will contact, the composition is said to be isotonic. When a composition is isotonic with a body fluid, the size of its ions is equal to that of the physiological fluid. The salts and ions in physiological fluids remain in their source fluid and reach osmotic balance after crossing the cell membrane. A solution is isotonic to a living cell if there is no net gain or loss of water within the cell or no other changes in the cell ultrastructure when in contact with the living cell.
[0078] Hypertonic solutions cause water to move outward from the interior of cells (because water moves outward to reach equilibrium with high salt levels outside the cells). This dehydration of cells is concentration-dependent and causes osmotic stress, which may increase reactive oxygen species within minutes of contact, cause cytoskeletal reorganization, and damage DNA and mitochondrial function. Most current genital products are hypertonic solutions, which cause epithelial cells and sperm to die after contact. Hypotonic solutions cause water to move into cells, causing cell rupture and death. Some physiological fluids have salt levels that deviate from those in blood and tissues and may have specific functions. For example, the low osmotic pressure of cervicovaginal fluids promotes lysis and death of cervical epithelial cells as part of normal vaginal function. Another example is that the higher osmotic pressure of semen protects sperm, allowing them to balance between the semen mixed in the vagina after ejaculation and the lower osmotic pressure of cervicovaginal secretions.
[0079] Related to osmotic pressure is osmosis, the movement of solvent from an area of high solute concentration through a semipermeable membrane to an area of low solute concentration to achieve equilibrium. The osmotic pressure of a solution is the pressure that must be applied to resist the flow of solvent through a semipermeable membrane.
[0080] In certain embodiments, the compositions of the present disclosure further include an osmotic pressure regulator to adjust the osmotic pressure of the composition. Example osmotic pressure regulators include electrolytes, monosaccharides or disaccharides, inorganic salts (e.g., sodium chloride, calcium chloride, potassium chloride, sodium sulfate, magnesium chloride) or a combination thereof. In certain embodiments, the osmotic pressure regulator can be glucose, sucrose, sodium chloride, potassium chloride, calcium chloride, sodium sulfate, magnesium chloride, glucose, mannitol or any combination thereof.
[0081] In certain embodiments, the osmotic pressure of the composition ranges from about 120 mOsm / kg to about 450 mOsm / kg or from about 240 mOsm / kg to about 450 mOsm / kg. In certain embodiments, the osmotic pressure of the composition of the present disclosure is about 120 mOsm / kg, about 125 mOsm / kg, about 130 mOsm / kg, about 135 mOsm / kg, about 140 mOsm / kg, about 145 mOsm / kg, about 150 mOsm / kg, about 155 mOsm / kg, about 160 mOsm / kg, about 165 mOsm / kg, about 170 mOsm / kg, about 175 mOsm / kg, about 180 mOsm / kg, about 185 mOm / kg, about 190 mOm / kg, about 195 mOm / kg, about 200 mOm / kg, about 205 mOm / kg, about 210 mOm / kg, about 215 mOm / kg, about 220 mOm / kg, about 225 mOm / kg, about 230 mOm / kg, about 235 mOm / kg, about 240 mOm / kg, about 245 mOm / kg, about 250 mOm / kg, about 255 mOm / kg, about 260 mOm / kg, about 265 mOm / kg, about 270 mOm / kg, about 275 mOm / kg, about 280 mOm / kg, about 285 mOm / kg, about 290 mOm / kg, about 295 mOm / kg, about 300 mOm / kg, about 305 mOm / kg, about 310 mOm / kg, about 315 mOm / kg, about 320 mOm / kg, about 325 mOm / kg, about 330 mOm / kg, About 335 mOsm / kg, about 340 mOsm / kg, about 345 mOsm / kg, about 350 mOsm / kg, about 355 mOsm / kg, about 360 mOsm / kg, about 365 mOsm / kg, about 370 mOsm / kg, about 375 mOsm / kg, about 380 mOsm / kg, about 385 mOsm / kg, about 390 mOsm / kg, about 395 mOsm / kg, about 400 mOsm / kg or about 450 mOsm / kg.
[0082] In certain embodiments, the osmotic pressure of the topical composition matches the normal physiological genital fluid pH of the subject (e.g., CVF, urethral secretions, semen, mycolipid) or the anogenital tissue of the subject (e.g., vaginal mucosa, anogenital skin), or the appropriate osmotic pressure of the applicable method. In certain embodiments, the osmotic pressure ranges from about 125 mOsm / kg to about 240 mOsm / kg. These embodiments match the low osmotic pressure of the CVF, which helps the dissolution of vaginal epithelial cells and the "self-cleaning" of the vagina. This cell lysis releases glycogen, which is used by healthy genital microorganisms for growth and development. These embodiments are very suitable for intravaginal delivery. In other embodiments, the osmotic pressure ranges from about 240 mOsm / kg to about 280 mOsm / kg. These embodiments match the osmotic pressure of the anogenital tissue and are very suitable for skin contacting the surface of the anogenital tissue. In a specific embodiment, the osmotic pressure ranges from about 280 mOsm / kg to about 450 mOsm / kg to match the deposition osmotic pressure of semen in the vagina. In certain embodiments, osmotic pressure can be expressed in milliosm / kg or mOsm / L. Osmotic pressure is the osmotic pressure of solutes per kilogram of solvent (Osm). Depending on the density of the solvent, osmotic pressure and osmolality (Osm per liter of solutes in solution) may be different. In certain embodiments, osmotic pressure and osmolality values can be used essentially interchangeably.
[0083] In certain embodiments, the topical isotonic composition further comprises a solvent (eg, an aqueous solvent, water) in an amount greater than about 88% (eg, ranging from about 88% to about 98%). In further embodiments, the solvent comprises water.
[0084] Topical penetration enhancers
[0085] There are many advantages to delivering drugs to the skin via a topical route. It is comfortable, convenient, and non-invasive for the patient. It avoids the problems of uneven absorption and metabolism rates that may be encountered with oral treatments, as well as other inherent inconveniences (such as gastrointestinal irritation and the need to take the drug after meals in some cases or on an empty stomach in other cases). This topical treatment avoids the risk of high levels of systemic drug and possible adverse reactions.
[0086] However, delivering drugs to the skin via topical routes is often challenging. The skin is a structurally complex, relatively thick membrane. Molecules that enter and pass through intact skin from the environment must first penetrate the stratum corneum and anything on its surface. The stratum corneum is a layer approximately 10-15 microns thick and is composed of densely packed, highly keratinized cells on most body sites. The high degree of keratinization within these cells and their dense packing are believed to be the primary factors that create a substantially impermeable barrier to the skin in most situations. For many drugs, the rate of penetration through the skin is extremely low without the use of some means of increasing skin permeability. Because the stratum corneum of many inflammatory skin lesions is often thicker than normal skin, penetration of topical drugs into the affected skin area is particularly difficult.
[0087] In order to increase the degree and speed of drug penetration through the skin, various methods have been used, each of which involves the use of chemical penetration enhancers or physical penetration enhancers. Physical penetration enhancers include electrophoretic techniques such as ion permeation. Ultrasound (or "sonophoresis") has also been studied as a physical penetration enhancer. Chemical penetration enhancers are more commonly used. These chemical penetration enhancers are topically applied simultaneously with the drug or in some cases before the drug to increase the permeability of the stratum corneum, thereby enhancing the penetration of the drug through the skin. Ideally, these chemical penetration enhancers (or "penetration enhancers" as referred to herein) are harmless compounds that are only used to promote the diffusion of drugs through the stratum corneum.
[0088] A variety of compounds that enhance skin permeability are known and described in the literature and literature. Compounds used to enhance skin permeability include: sulfoxides, such as dimethyl sulfoxide (DMSO) and decamethyl sulfoxide (C10MSO); ethers, such as ethylene glycol monoethyl ether (commercially known as ) and ethylene glycol monomethyl ether; surfactants such as sodium laurate, sodium laurate sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, Poloxamer (231, 182, 184), Tween (20, 40, 60, 80), and lecithin (U.S. Pat. No. 4,783,450); 1-substituted azepan-2-ones, particularly 1-n-dodecylcycloheptane-2-one (trademark of Nelson Research & Development Co. esters of fatty acids, such as isopropyl creatine, isopropyl palmitate, methyl propionate and ethyl oleate; polyols and their esters, such as propylene glycol, ethylene glycol, glycerol, butylene glycol, polyethylene glycol and polyethylene glycol monolaurate (PEGML; see, e.g., U.S. Pat. No. 4,568,343); amides and other nitrogen-containing compounds, such as urea, dimethylacetamide (DMA), dimethylformamide (DMF), 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine and triethanolamine; terpenoids; alkanones; and organic acids, particularly salicylic acid and salicylates, citric acid and succinic acid. The book, Transdermal Penetration Enhancers (Smith et al., ed., CRC Press, 1995), provides a comprehensive overview of the field and background information on a variety of chemical and physical enhancers.
[0089] For a long time, it has been believed that strong bases such as NaOH are not suitable as penetration enhancers because they can damage the skin. It is now found that by exposing the skin to alkaline substances or alkaline solutions, the skin permeability of various drugs can be enhanced without damaging the skin, which can be achieved by contacting the formulation or patch of the skin. A variety of alkalis or alkalis of different concentrations can be used to obtain the required pH value on the skin. Therefore, the pH value selected should be low enough not to cause skin damage, but high enough to enhance the penetration of various active agents to the skin. Therefore, in some embodiments, the optimization of the amount of alkali in any patch or formulation is crucial to increase the flux of the drug through the body surface while minimizing the possibility of any possible skin damage. Typically, this means that the body surface pH contacted with any formulation or drug delivery system may be in the range of about pH 8.0 to about pH 13.0, about pH 8.0 to about pH 11.5, about pH 8.5 to about pH 11.5, or about pH 8.5 to about pH 10.5. In certain embodiments, the pH is in the range of about pH 9.5 to about pH 11.5, or about pH 10.0 to about pH 11.5.
[0090] In one embodiment, the pH at the body surface is the primary design consideration, i.e., the formulation or system is designed to provide the desired pH at the body surface. Anhydrous formulations and transdermal systems may not have a measurable pH, and the formulation or system may be designed to provide a target pH at the skin surface. Moisture from the body surface can migrate into the formulation or system, dissolve the base, and release the base into solution, which then provides the desired target pH at the body surface. In these cases, it may be desirable to use a hydrophilic composition. In addition, when using a water-based formulation, the pH of the formulation may change over time after application to the skin. For example, gels, solutions, ointments, etc. may experience a net loss of water after application to the body surface, i.e., the amount of water lost is greater than the amount of water from the body surface. In this case, this problem can be easily solved by designing a water-based formulation to provide a target pH at the body surface.
[0091] In other embodiments, the pH of the drug composition in the formulation or delivery system will be in the range of about pH 8.0 to about pH 13.0, about pH 8.0 to about pH 11.5, about pH 8.5 to about pH 11.5, or about pH 8.5 to about pH 10.5. In certain embodiments, the pH will be in the range of about pH 9.5 to about pH 11.5, or about pH 10.0 to about pH 11.5. In one embodiment, the pH of the formulation is higher than the pH of the body surface. For example, if a water-based formulation is used, the moisture from the body surface can dilute the formulation, thereby providing a different pH at the body surface, generally lower than the pH of the formulation itself.
[0092] In one embodiment, the body surface is exposed to an alkali or alkaline solution for a sufficient period of time to provide a high pH on the skin surface, thereby forming a channel for drug penetration in the skin or mucous membrane. The expected drug flux is proportional to the concentration of the solution and the exposure time. However, ideally, a balance needs to be achieved between maximizing drug flux and minimizing skin damage. This balance can be achieved in a variety of ways. For example, skin damage can be reduced by selecting a lower pH in the range of 8.0 to 13.0, by exposing the skin to the formulation or system for a shorter time, or by including at least one additive that reduces irritation. Alternatively, the patient can be advised to change the application site each time it is used.
[0093] Although certain amounts are described below, it should be understood that for all inorganic and organic bases described herein, the optimal amount of any such base depends on the strength or weakness of the base, its molecular weight, and other factors, such as the number of ionizable sites in the active agent being administered and the presence of any acidic materials in the formulation or patch. A skilled artisan can readily determine the optimal amount of any particular base to optimize the enhancement effect while eliminating or at least greatly reducing the potential for damage to the body surface.
[0094] Examples of inorganic bases include inorganic hydroxides, inorganic oxides, inorganic salts of weak acids, and combinations thereof. Some inorganic bases are aqueous solutions thereof having high pH values and are acceptable as food or pharmaceutical additives. For example, these inorganic bases include aqueous ammonia, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, magnesium oxide, calcium oxide, Ca(OH)2, sodium acetate, sodium borate, sodium borite, sodium carbonate, sodium bicarbonate, sodium phosphate, potassium carbonate, potassium bicarbonate, potassium citrate, potassium acetate, potassium phosphate, and ammonium phosphate, and combinations thereof.
[0095] Inorganic hydroxides include ammonia, alkali metal hydroxides, alkaline earth metal hydroxides, and mixtures thereof. Some inorganic hydroxides include ammonia; monovalent alkali metal hydroxides such as sodium hydroxide and potassium hydroxide; divalent alkaline earth metal hydroxides such as calcium hydroxide and magnesium hydroxide; and combinations thereof.
[0096] The amount of inorganic hydroxide included in the formulations and systems disclosed herein is generally expressed as 0.3-7.0 W / V%, 0.5-4.0 W / V%, 0.5-3.0 W / V% or 0.75-2.0 W / V%, as a drug reservoir or patch for topical application formulations or drug delivery systems.
[0097] Inorganic oxides include magnesium oxide, calcium oxide and the like.
[0098] The amount of inorganic oxide included in the formulation and system may be significantly higher than the above values for the inorganic hydroxide, and may be as high as 20% by weight, and in some cases may even be as high as 25% by weight or more, but generally will be in the range of about 2-20% by weight. These amounts may be adjusted according to the presence of any base neutralizing species.
[0099] Inorganic salts of weak acids include ammonium phosphate (diac), alkali metal salts of weak acids such as sodium acetate, sodium borate, sodium borate, sodium carbonate, sodium bicarbonate, sodium phosphate (tribasic), sodium phosphate (diac), potassium carbonate, potassium bicarbonate, potassium citrate, potassium acetate, potassium phosphate (diac), potassium phosphate (tribasic); weak acid salts of alkaline earth metals such as magnesium phosphate and calcium phosphate; and combinations thereof.
[0100] The organic bases suitable for use in the present disclosure are compounds with amino, amide, oxime, cyano, aromatic or non-aromatic nitrogen-containing heterocycles, urea groups and combinations thereof. Specifically, examples of suitable organic bases include, but are not limited to, nitrogen bases, such as primary amines, secondary amines, tertiary amines, aminomethane, guanidine, hydroxylamine, cyanoguanidine, cyanoguanidine, oxime, groups containing cyano (—CN), aromatic and non-aromatic nitrogen-containing heterocycles, urea and mixtures thereof. In certain embodiments, the organic base is primary amines, secondary amines, tertiary amines, aromatic and non-aromatic nitrogen-containing heterocycles and mixtures thereof.
[0101] For all permeability enhancing groups herein, the optimal amount of any particular agent depends on the strength of the group, the molecular weight of the group, and other factors, such as the number of ionizable sites in the drug being administered and any other acidic species in the formulation or patch. The optimal amount of any particular agent can be readily determined by ensuring that the pH provided by the formulation upon application at the skin surface is in the range of about pH 7.5 to about pH 13.0, about pH 8.0 to about pH 11.5, or about pH 8.5 to about pH 10.5. In certain embodiments, the pH will be in the range of about pH 9.5 to about pH 11.5, or about pH 10.0 to about pH 11.5. This operation ensures that the therapeutic effect is maximized while eliminating or at least greatly reducing possible damage to the body surface.
[0102] Other penetration enhancers will be known to those of ordinary skill in the art of topical administration and / or are described in the relevant texts and literature. See, for example, "Transdermal penetration enhancers for drug entry / through the skin", Dragicevic & Maibach. (Springer Link, 2017).
[0103] Other active ingredients
[0104] In one embodiment, it is contemplated to improve anogenital sensory function by administering one or more additional drugs. In certain embodiments, the second therapeutic agent is an antioxidant, anti-inflammatory, antimicrobial including antibacterial, antihistamine, mast cell stabilizer, antiviral and antifungal, anti-angiogenic, anti-apoptotic, lubricant, vasodilator and / or secretagogue.
[0105] Inflammation is induced by the process of leukocyte adhesion and neovascularization. Therefore, other anti-inflammatory drugs can be used before, after or simultaneously with the use of the compounds described herein. Anti-inflammatory drugs can be selected from drugs related to corticosteroids, including but not limited to dexamethasone, flumethasone, medroxyprogesterone, betamethasone, triadimefon, triadimefon acetone, prednisone, prednisolone, hydrocortisone, rimexolone and pharmaceutically acceptable salts thereof, prednicasone, deflazacort, halometasone, ticolasone, prednisolone, prednival, primadone, methylprednisolone, methylprednisone, methylprednisone, maziprednisolone, isofluprednisolone, halopednisolone acetate, haloxanide, formocort, fluprednisolone, fluprednidine acetate, fluprednisolone acetate, fluocortolone ... Fluocinolone butyl ester, fluocinolone, fluocinolone acetate, flunisolide, flumethasone, fludrocortisone, fluclofenide, enoxapolone, difluprednate, diflucortisone, dichlorocortisone diacetate, desoxymethasone (desoxymethasone), norsinesonide, desinolone, cortisone, corticosterone, cortisone, chlorprednisolone, clocortisone, clobetasone, cloprednisolone, carfinpristone, budesonide, beclomethasone, aminoxone, isopregnantane acetone, alclomethasone, 21-acetoxypregnenolone, triamcinolone acetonide, desoxycortisone acetate, desoxycortisone, RU-26988, budesonide, desoxycortisone, etc. In addition, anti-inflammatory drugs also include 5-aminosalicylic acid (5-ASA) compounds, such as sulfasalazine (Azulfidine), olsalazine (Dipentum) and mesalamine (mesalamine) (e.g. Pentasa, Asacol, Dipentum, Colazal, Rowasa enema and Canasa suppository). Similarly, anti-inflammatory drugs can also be selected from cyclosporine-related drugs (such as calcineurin antagonists), including but not limited to cyclosporine family members, and other related calcineurin antagonists, including sirolimus, tacrolimus and pimecrolimus. Similarly, anti-inflammatory drugs can be selected from cyclosporine-related drugs (such as calcineurin antagonists), including but not limited to cyclosporine family members and other related calcineurin antagonists, such as sirolimus, tacrolimus and pimecrolimus.Alternatively, the anti-inflammatory drug may be selected from the group of nonsteroidal anti-inflammatory drugs (NSAIDs), including but not limited to acetaminophen, aspirin, ametezine, ethaminophen, afenamic acid, bendazolic acid, benzaclorac, bromoflurane, bufloxacin, bufloxacin, phthalic acid, flunolanone, flupronone, ibufenac, indomethacin, isofuranolide, isonitropin, isoflurane, ketopropionic acid, lonazolidinone, loxolotol, mestilbene, meclocycline, metriac, miloxicam, miloxicam, miloprofen, captopril, thiophene, thiazolidine, tiacloprid ... and its derivatives (e.g. aspirin), fondamate, thiophene, thiophene-4, trifluprofen, tolchloranilide, tolconazole, valdone, clesabutin, ximoprofen, zaltoprofen, aspirin, acetone, bomadizoic acid, captopto, crevenzine, difluprednisolone, enflurane, flujuicy acid, flufenamic acid, fluflufenic acid, flubiprofen, flufenamic acid, flufenamic acid, fluniprofen, glycine, silicic acid, tioclofenac, telometin, valdioxalic acid, ufsalin, usprofil, enmegaline, zinc propoxylic acid, zinc propoxylic acid and various related substances. Additionally, immunomodulators such as 6-mercaptopurine (6-MP), azathioprine (Imuran), methotrexate (Rheumatrex, Trexall), infliximab (Remicade), and adalimumab (Humira) may also be used.
[0106] The following classes of therapeutic agents may be useful in combination with, before, after, or simultaneously with the compounds described herein, including antihistamines, such as alkylamines, ethanolamines, and benzothiophenes, for example, chlorpheniramine hydrochloride, danamin hydrochloride, diphenhydramine hydrochloride, promethazine hydrochloride, aclivastine, azatidine hydrochloride, azilastine hydrochloride, brompheniramine hydrochloride, carbinozine hydrochloride, cetirizine hydrochloride, clemastine fumarate, cypromazine hydrochloride, cypromazine hydrochloride, hydroxypromazine hydrochloride, caffeine fumarate, tetraflucarbamazine nitrate, pheniramine fumarate, tripromazine fumarate, promethazine fumarate, tripromazine fumarate, and tripromazine fumarate hydrochloride. In certain embodiments, formulations for nasal or ocular administration include one or more antihistamines.
[0107] Mast cell stabilizers, such as sodium cromolyn and nedocromil, are one class of therapeutic agents that may be used in conjunction with the compounds of the present disclosure, either before, after, or simultaneously with the compounds described herein.
[0108] Cells with impaired autonomy and ischemic processes may induce oxidative stress. Therefore, it may be useful to use antioxidants before, after, or simultaneously with the compounds described herein. Examples of suitable antioxidants suitable for the methods described herein include, but are not limited to, ascorbic acid, tocopherols, tocotrienols, carotenoids, glutathione, α-lipoic acid, ubiquitinol, bioflavonoids, carnitine, and superoxide dismutase analogs, such as 2,2,6,6-tetramethyl-1-piperidinyloxy free radical (TEMPO), DOXYL, PROXYL nitrogen oxide compounds; 4-hydroxy-2,2,6,6-tetramethyl-1-piperidinyloxy free radical (Tempol), M-40401, M-40403, M-40407, M-40419, M-40484, M-40587, M-40588, and the like.
[0109] In some embodiments described herein, methods are provided in which anti-apoptotic therapeutic agents can be administered in combination with the disclosed compounds, before, after, or simultaneously with the disclosed compounds. Examples of suitable anti-apoptotic agents include inhibitors of, for example, cysteine proteases, feline proteases, and TNF-α.
[0110] Another class of therapeutic agents that may be useful in combination with, before, after, or concurrently with the compounds of the present disclosure is an antimicrobial agent. Suitable antimicrobial compounds include, but are not limited to, penicillins, such as amoxicillin, ampicillin, ateclocillin, carbenicillin, cloxacillin, dicloxacillin, fluxacillin, mezacillin, nadram penicillin, penicillin, piperacillin, ticarcillin, and the like; beta-lactamase inhibitors; carbapenems, such as eltapen, imipenem, meropenem, and the like; cephalosporins, such as cefaclor, cefmandol, cefuroxime, cefuroxime, cefuroxime, cefoperazone ... ketones, etc.; quinolones, such as ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin, momofloxacin, norfloxacin, ofloxacin, tofafloxacin, etc.; macrolide drugs, such as azithromycin, clarithromycin, dilmidromycin, erythromycin, milbemycin, torezamycin, etc.; monosporins, and the like; carbapenemicarcins, such as loracabate, etc.; streptomycin; sulfonamides, such as mephenate, prontocillin, sulfadiazine, sulfadiazine, sulfanilide, sulfaaminosalicylic acid, sulfathiazolazole, sulfathiaphene, triplet, sulfadiazine, sulfathiazine, and the like; other antimicrobial drugs, such as metronidazole; and combination drugs such as sulfamethoxazole, triple combination therapy, etc.
[0111] Other antimicrobial agents include the class of antiviral agents. Antiviral agents include, but are not limited to, therapeutic agents such as entry inhibitors, reverse transcriptase inhibitors, nucleoside or nucleotide analogs, protease inhibitors, and agents that inhibit the release of viruses from host cells. Some examples of such therapeutic agents include, but are not limited to, abacavir, acyclovir, adefovir, amantidine, ampurina, arbidol, atazanavir, etlip, briveridine, cidofovir, conbivir, darunavir, delavirine, didanosine, docosanol, edoban, emtecabine, enfovetide, entecavir, famciclovir, foscanide, fosina, fovenate, foprenamate, fluconazole, norfloxacin, Gan Yongsheng, gadida, ebasitin, immunotoxin, iodine uracil, imequin, indoletriol, interferon Type III, interferon type II, interferon type I, interferon, lamivudine, lopinavir, loviride, maraviroc, moloxitin, nelfinavir, nelfinavir, nevapitin, oseltinavir, pesinavir, peramivir, pleconaril, podoxime, latinavir, ribavarin, ribavarin lactase, trifluridine, trivalent, tromantidine, truvada, valasiclovir, valgaciclovir, vicriloc, vidarabine, viramidine, viradabine, cidovudine, xidoradine, zidovudine, etc.
[0112] In certain embodiments, formulations for application to the skin include one or more antimicrobial agents or antibiotics.
[0113] Secretagogues may also be used before, at the same time as, or after pirenzepine. Increasing the secretion of mucin or other fluids in the eye may be beneficial. Examples include, but are not limited to, diquafasol, rebamipide, and eicosanoid 15-(S)-HETE.
[0114] One class of therapeutic agents that may be useful when taken before, after, or simultaneously with pirenzepine are vasodilators, which help relax blood vessels to improve blood flow. These include phosphodiesterase inhibitors (papaverine, pentoxil, and amrinone), local anesthetics (lidocaine), calcium channel blockers (nicardipine, verapamil, nifedipine, and magnesium sulfate), direct vasodilators (sodium nitroprusside, prostaglandin E1, nitroglycerin, and hydrazine hydrate), and alpha-antagonists (phentolamine and chlorpromazine).
[0115] Alprostadil is a vasodilator that is effective in treating ED in many men. Alprostadil is a synthetic analog of prostaglandin E1 (PGE1) with multiple pharmacological actions. Alprostadil acts as an agonist by binding to prostaglandin receptors (such as EP2), thereby activating adenylate cyclase, leading to the accumulation of 3'5'-cAMP (cyclic adenosine monophosphate).
[0116] Non-limiting examples of phosphodiesterase type 5 inhibitors include, but are not limited to, avanafil, lodenafil, mirodenafil (pKa of 6.0), sildenafil (or an analog thereof, such as sildenafil hydrochloride, hydroxysildenafil hydrochloride, or dimethylsildenafil), tadalafil (pKa of 18), vardenfil (pKa of 3.4, 6.7, 8.8, and 14, respectively), udenafil (pKa of 10.53), ethyl sildenafil, or thiomethylthiosildenafil.
[0117] Many phosphodiesterase type 5 inhibitors are commercially available. In some cases, the phosphodiesterase type 5 inhibitor is available as a racemic mixture, such as tadalafil (e.g., (R,R)-tadalafil, (R,S)-tadalafil, (S,R)-tadalafil, and (S,S)-tadalafil). However, in other cases, one optical isomer may be present in greater abundance than another. For example, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or at least about 95% of the phosphodiesterase type 5 inhibitor may be present as one optical isomer in a composition. Techniques for preparing or separating phosphodiesterase type 5 inhibitors are known; for example, see Gao et al., 2007, "Separation of Two Optical Isomers of Tadalafil by High Performance Liquid Chromatography," Journal of Chromatography, 45: 540-543.
[0118] In some embodiments, the constituent can also include a nitric oxide donor, such as L-arginine and / or L-arginine hydrochloride. In some cases, this nitric oxide donor can be used to increase the local blood flow of the constituent application site, which may enhance the transmission of the pharmaceutical agent. The nitric oxide donor can be present in the constituent at any suitable concentration. For example, in some cases, the concentration of the nitric oxide donor is at least about 1%, at least about 2%, at least about 3%, at least about 4%, at least about 5%, at least about 6%, at least about 7%, at least about 7.5%, at least about 8%, at least about 9% or at least about 10% of the constituent weight. In some cases, one or more nitric oxide donors (such as 2,3,4,5,6,7,8,9,10 kinds of nitric oxide donors) can be used. In some cases, there may not be more than 3,5,7 or 10 kinds of nitric oxide donors in the constituent.
[0119] As described herein, "nitric oxide donor" refers to a compound that can release nitric oxide and / or transfer a nitric oxide group to another molecule directly or indirectly through a biological process. The nitric oxide donor can release nitric oxide into the skin and muscles and / or circulatory system tissues near the skin surface. Non-limiting examples of nitric oxide donors include arginine (e.g., L-arginine and / or D-arginine), arginine derivatives (e.g., L-arginine hydrochloride and / or D-arginine hydrochloride), nitroglycerin, polysaccharide-bound nitric oxide nucleophile adducts, N-nitroso-N-substituted hydroxylamines, 1,3-(nitroxymethyl)phenyl-2-hydroxybenzoate, etc., and any combination of the above compounds and / or other compounds.
[0120] In addition to L-arginine and L-arginine hydrochloride, other non-limiting examples of nitric oxide donors include D, L-arginine, D-arginine or L-arginine and / or D-arginine alkyl (e.g., ethyl, methyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, etc.) esters (e.g., methyl ester, ethyl ester, propyl ester, butyl ester, etc.) and / or salts thereof, as well as derivatives of arginine and other nitric oxide donors. For example, non-limiting pharmaceutically acceptable salts include hydrochlorides, glutamate, butyrate or glycolate (e.g., L-arginine glutamate, L-arginine butyrate, L-arginine glycolate, D-arginine hydrochloride, D-arginine glutamate, etc.). Examples of other nitric oxide donors include compounds based on L-arginine, such as but not limited to L-homoarginine, N-hydroxy-L-arginine, nitrosated L-arginine, nitrosated N-hydroxy-L-arginine, citrulline, ornithine, linsidomine, nipril, etc., and salts thereof (e.g., hydrochloride, glutamate, butyrate, glycolate, etc.), and any combination of the above compounds and / or other compounds. Other non-limiting examples of nitric oxide donors also include S-nitrosothiol, nitrite, 2-hydroxy-2-nitrosohydrazine, etc., or various forms of nitric oxide synthase substrates. In some cases, a nitric oxide donor can be a compound that stimulates the production of nitric oxide in the body. Examples of such compounds include but are not limited to L-arginine, various forms of nitric oxide synthase substrates, certain cytokines, adenosine, kinins, caluretoin, bisacodyl, phenolphthalein, OH-arginine or endothelin, etc., and any combination of the above compounds and / or other compounds.
[0121] Other agents such as antimicrobial agents may also be added to prevent deterioration during storage, i.e., inhibit the growth of microorganisms such as yeast and mold. Suitable antimicrobial agents are generally selected from methyl and propyl esters of parahydroxybenzoic acid (i.e., methyl and propyl paraben), sodium benzoate, sorbic acid, imine urea, sulfites, peroxides, perborates, and combinations thereof.
[0122] The formulation may also contain cosmetic agents. Examples of cosmetic agents include fragrances, pigments, colorants, essential oils, skin sensates, and astringents. Suitable cosmetic agents include clove oil, menthol, camphor, eucalyptus oil, eugenol, methyl lactate, bisabotol, witch hazel distillate, and green tea extract.
[0123] Spices are aromatic substances that can give pleasant aromas. Typical spices include aromatic materials (such as rose petals, gardenia, jasmine, etc.) extracted from plant sources, which can be used alone or in combination to make essential oils. In addition, alcohol extracts can also be prepared to prepare spices. However, due to the relatively high cost of obtaining spices from natural substances, the modern trend is to use synthetic spices in bulk products. One or more spices can be selected as selectively included in the sunscreen composition, and its amount is between about 0.001 to about 5 weight percents, or between about 0.01 to about 0.5 weight percents. If necessary, additional preservatives can also be used, which include well-known preservative combinations, such as benzyl alcohol, phenylethyl alcohol and benzoic acid, diazide urea, chlorobenzyl alcohol, iodopropynyl and butyl formate, etc.
[0124] In one embodiment, the present disclosure relates to a formulation prepared according to the description of WIPO patent application WO / 2020 / 198252 for treating peripheral neuropathy, comprising peranlanepine or a salt thereof, DMSO and a polyether surfactant, such as a polyalkoxyvinyl ether.
[0125] Ingredients table
[0126] The active agent can be used in any pharmaceutically acceptable effective form for the patient, for example, by cream, gel, ointment, emulsion, solution, lotion, suspension, tincture, paste, foam, aerosol, irrigant, spray, suppository or any other preparation or pharmaceutical composition suitable for topical administration. The topical preparation of the pharmaceutical composition can be provided as a topical composition, wherein the pharmacologically active ingredient is mixed with an excipient to form a semisolid consistency. Examples of such topical pharmaceutical compositions include, but are not limited to, gels, creams, emulsions, suspensions, emulsions, ointments, foams, pastes, etc. In addition, the topical pharmaceutical composition can also be formulated into a semi-liquid preparation. Examples of such topical pharmaceutical compositions include, but are not limited to, topical solutions, sprays, mists, drops, etc. In addition, the topical pharmaceutical composition can also be formulated into a dry powder form. The pharmaceutical composition can also be administered via a transdermal patch.
[0127] As is well known, an ointment is a semisolid preparation, usually based on petrolatum or other petroleum derivatives. As an ointment, the consistency of the composition is suitable for even application to the skin. In addition, the ointment may have a high viscosity and can remain in contact with the skin regardless of sweating, excessive moisture or environmental conditions. It is known to those skilled in the art that the specific ointment base to be used can not only provide the best drug delivery effect, but also provide other desired properties, such as emollient or similar properties. Like other carriers or carriers, the ointment base should be inert, stable, non-irritating and non-sensitizing. As explained in Remington's Science and Practice of Pharmacy, 19th edition (Easton, Pennsylvania: Mack Publishing Company, 1995), pages 1399-1404, ointment bases can be divided into four categories: oil-containing bases, emulsifiable bases, emulsion bases and water-soluble bases. Oily ointment bases include vegetable oils, animal fats, and semisolid hydrocarbons extracted from petroleum. Emulsifiable ointment bases, also called absorbent ointment bases, contain little or no water and include, for example, hydroxystearyl sulfate, anhydrous lanolin, and hydrophilic petrolatum. Emulsion-type ointment bases are water-in-oil (W / O) emulsions or oil-in-water (O / W) emulsions and include, among others, cetyl alcohol, glyceryl monostearate, lanolin, and stearic acid. Some water-soluble ointment bases are prepared from polyethylene glycols of varying molecular weights; again, see The Science and Practice of Remington's Pharmacy for more information.
[0128] Creams, also well known in the art of pharmaceutical formulation, are viscous liquids or semisolid emulsions, either oil-in-water or water-in-oil. The cream base is water-washable and contains an oil phase, an emulsifier, and an aqueous phase. The oil phase, also called the "inner" phase, is usually composed of petrolatum and cetyl or stearyl alcohol. The aqueous phase usually, although not necessarily, exceeds the oil phase in volume and usually contains a humectant. The emulsifier in a cream formulation is usually a nonionic, anionic, cationic, or amphoteric surfactant.
[0129] Gels are semisolid, suspension-type systems that are well known in the field of pharmaceutical formulations. The gel-forming agent used herein can be any gelling agent commonly used in the field of pharmaceutical formulations for preparing topical semisolid dosage forms. Single-phase gels contain organic macromolecules that are substantially uniformly distributed in a carrier liquid (usually water, but can also contain alcohol and optional oil). In order to prepare a uniform gel, a dispersant such as an alcohol or glycerol can be added, or the gelling agent can be dispersed by homogenization, mechanical mixing or stirring, or a combination thereof. The amount of gelling agent used varies greatly, typically from about 0.1% to about 2.0% by weight of the total composition. Gel-forming agents also work through the principle of copolymerization. Under alkaline pH conditions, carbomers cross-link in the presence of water and form a gel-like structure. The degree of polymerization depends on the pH value. At a threshold pH, the polymer grade reaches a maximum viscosity.
[0130] Emulsions are preparations that are applied to the surface of the skin without rubbing, usually semi-liquid preparations, which contain solid particles, including active ingredients, in a water or alcohol base. Emulsions are usually suspensions of solids, and for the purposes of this article, they include liquid oil emulsions of the oil-in-water type. Since more mobile combinations are easy to apply to large areas of the body, emulsions may be ideal preparations here. It is usually required that the insoluble matter in the emulsion is a fine powder. Emulsions usually contain suspending agents to produce a better dispersion effect, as well as compounds that help to locally position and maintain the active ingredient in contact with the skin, such as methylcellulose, sodium carboxymethylcellulose or the like.
[0131] Ointments are semisolid dosage forms in which the active ingredient is suspended in an appropriate base. Depending on the nature of the base, ointments are classified as lipid ointments or ointments made from a single-phase hydrogel. The base in lipid ointments is usually vaseline or hydrophilic vaseline or the like. Ointments made from a single-phase hydrogel usually contain carboxymethylcellulose or the like as a base.
[0132] Plasters consist of a paste-like mixture that can be applied directly to the body or after saturating a base material such as cloth. Drugs, including pharmacologically active bases, can be dissolved or dispersed in the plaster to make a medicated plaster.
[0133] A bioadhesive is a preparation that can adhere to the surface of human tissue. Polymeric bioadhesive preparations are well known in the art; for example, see Heller et al., "Biodegradable polymers as drug delivery systems", in Chasin, M. and Langer, R., eds: Dekker, NY, pp. No. 6,201,065. Suitable non-polymer bioadhesives are also known in the art, including certain fatty acid esters (U.S. Pat. No. 6,228,383).
[0134] The pharmaceutical composition for transdermal administration can be, for example, a hydrogel containing pirenzepine, which is combined with a paste composition. Its purpose is to maintain close contact with the epidermis of the subject for a long time. An exemplary paste composition can include an overall layer, which is a mixture of a muscarinic acetylcholine receptor antagonist with a silicone adhesive or an acrylic acid vinyl ester adhesive in a solvent such as methylene chloride, ethyl acetate, isopropyl myristate and propylene glycol. The mixture is then squeezed onto a polyester base film with a precision wet film applicator to a uniform thickness of or above 100 microns. The solvent is allowed to evaporate in a drying oven, and the resulting "patch" is then trimmed to an appropriate size.
[0135] Suppositories are another carrier that can be used to deliver copper ion therapy to the vagina and rectum. Suppositories are commonly used in the vagina and rectum (anus) as a means of dispensing various active ingredients or drugs. Suppositories come in a variety of shapes, including ovoid, spherical, conical and bullet-shaped, and in varying sizes. Suppositories usually weigh between 1 and 5 grams. Suppositories can be solid and consist of a mixture of a suitable suppository base material and an active ingredient or drug. In addition, suppositories can also be made by wrapping non-solid active ingredients or drugs in a solid outer wall of a suppository base material. The suppository base material used in the suppository allows it to dissolve or melt when exposed to moisture (body fluids) or heat (body temperature) in the vagina or rectum (rectum or anal canal), thereby releasing the active ingredient or drug into the vagina or rectum. Suitable suppository base materials include oil-containing (fat) base materials, including cocoa butter, cocoa butter oil and synthetic triglycerides, or water-soluble or miscible base materials, including glycerin gelatin and polyethylene glycol (PEG) polymers. The matrix material is preferably nontoxic, non-irritating, inert and biocompatible. Suppositories suitable for a certain aspect of the disclosure can be prepared in various ways according to traditional suppository preparation methods, including compression molding and melt molding. Suppositories can be inserted into the vagina and rectum with fingers, and applicators can also be provided for the suppositories to facilitate their insertion into the vagina and rectum.
[0136] Another carrier for delivering treatment to the vagina is a tampon. The tampon used may be a commercially available tampon or similar product. The tampon may be one with a syringe, comprising a barrel containing an absorbent tampon body and a push rod at the front end opening of the barrel that can push the absorbent tampon body into the vagina to an appropriate distance, in the usual manner of tampon use. Another suitable tampon may be one without a syringe, i.e. a digital tampon, in which the absorbent tampon body is pushed into the vagina by fingers.
[0137] Another carrier for delivering treatment to anatomical tissue is a body wipe. The body wipe includes a thin sheet of material covered with a treatment agent that can be folded and overlapped for removal from a package. After removal from the package, the body wipe can be unfolded to its full size, which is much larger than the size in the folded state, and can be used to wipe the anatomical tissue to be treated, thereby delivering the copper ion treatment to the anatomical tissue.
[0138] Another carrier used for treatment is a wound dressing, such as a band-aid, gauze pad or similar device. Such a carrier can be selected from commercially available products and is used to temporarily cover and protect the affected area of the skin.
[0139] Another type of therapeutic carrier is a skin patch, such as a transdermal patch or a transdermal patch. A skin patch has a drug delivery surface containing the therapeutic agent and is surrounded by an adhesive border. The skin patch is applied to the skin and left in place for a period of time so that the drug delivery surface is in contact with the skin, allowing the active ingredient to diffuse through the skin to act locally or penetrate the capillaries to produce a more widespread systemic effect. Suitable transdermal patches include the transdermal and microneedle 3M drug delivery systems produced by 3M.
[0140] Methods of treatment using topically formulated pirenzepine
[0141] In some embodiments, the compounds can be used to treat and / or prevent anal sensory diseases or symptoms in a subject. Thus, in one aspect, a method for treating a sexual sensory disease or disorder in a subject is provided, the method comprising topically administering to the anus of the subject a formulation comprising pirenzepine or a pharmaceutically acceptable salt or ester thereof, and a pharmaceutically acceptable excipient.
[0142] The benefits of topical administration include local administration of the therapeutic agent and minimal systemic side effects due to low systemic bioavailability. For example, topical formulations can be applied directly to the anogenital area of the subject, including the skin, vaginal mucosa, or anal mucosa. Topical administration methods are particularly suitable for topical administration of formulations. Suitable formulations and other carriers are discussed herein and are also described in Remington's Science and Practice of Pharmacy (20th Edition, Lippincott Williams & Wilkins, Baltimore, Maryland), the teachings of which are incorporated herein by reference in their entirety.
[0143] The pharmacokinetic characteristics of the administration of the composition can result in the administration of an effective dose of pirenzepine. The actual effective amount of the drug may vary depending on the specific drug or combination thereof used, the specific composition formulated, the mode of administration, and the age, weight, condition, and severity of the symptoms or condition being treated of the patient. The dosage for a specific patient can be determined by a person of ordinary skill in the art based on conventional considerations (e.g., by an appropriate conventional pharmacological regimen).
[0144] In other embodiments, provided herein is a method of improving skin sensitivity in the anogenital area comprising applying to the skin an effective amount of a topical composition comprising pirenzepine.
[0145] In some embodiments, provided herein is a method of improving symptoms of neuropathy, comprising applying an effective amount of a topical composition comprising pirenzepine to the skin of the anogenital region. In a preferred embodiment, the neuropathy is diabetic neuropathy.
[0146] In certain embodiments, the topical formulations provided herein are intended to be applied topically and non-invasively to the genital area, particularly the penis, either in its entirety, or better still, only to the glans penis. In addition, the composition can be applied to the shaft of the penis.
[0147] Drug administration
[0148] The method of administration of the pharmaceutically active composition can be different, and in some embodiments, it is related to the preparation being applied to the genital area affected by sensory disturbance. In certain embodiments, the preparation is topically applied to the genital area including skin, vaginal mucosa or anal mucosa. Gel, cream, ointment, paste, plaster or lotion can be applied to the affected skin area and massaged gently. Similarly, polymer or other bioadhesive preparations can be applied or dotted on the affected skin area. Solution can be applied in the same way, but more usually a dropper, cotton swab or the like can be used to carefully apply to the affected skin area. Vaseline can be applied around the affected skin to protect it from the stimulation that may be caused during the treatment process.
[0149] The dosage regimen will depend on a variety of factors, such as the size, severity, and responsiveness of the affected area to treatment, but is generally administered once or more times daily, with treatment cycles ranging from a few days to several months, or until healing or a significant reduction in the size and / or severity of the disturbance. The optimal dosage, method of administration, and repetition rate can be readily determined by an ordinary technician. Generally, it is expected that the formulation will be applied one to four times a day. For skin patches, suppositories, or other devices, the device is typically secured to the body surface, remains secured during the drug release period, typically between 8 and 72 hours, and is replaced as needed.
[0150] In certain embodiments, the amount of pirenzepine is sufficient to produce a therapeutic effect by eliminating, on average, at least about 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, greater than 90%, or substantially all of the symptoms.
[0151] In certain embodiments, an effective amount of pirenzepine is about 1×10 -11 , 1×10 -10 , 1×10 -9 , 1×10 -8 , 1×10 -7 , 1×10 -6 , 1×10 -5 , 1×10 -4 , 1×10 -3 , 1×10 -2 , 1×10 -1 , 1, 1×10 1 or 1×10 2 gram.
[0152] Methods for treating sensory disturbances include topical preparations.
[0153] It is contemplated that the total daily dose of the drug, as well as the weight concentration of the drug in the corresponding composition, may vary widely but are within the typical skill of the ordinary practitioner. The specific therapeutically effective dosage level for any particular patient and drug will depend on a variety of factors, including the disease being treated and the severity of the disease; the activity of the specific compound being used; the specific composition being used; the age, weight, general health, sex and dietary habits of the patient; the time of administration, route of administration and excretion rate of the specific drug being used; the duration of treatment; drugs used in combination or concomitantly with the specific compound being used; and similar factors well known in the medical art. For example, according to the art, the initial dose should be lower than the dose required to achieve the desired therapeutic effect, and the dose should be gradually increased until the desired effect is achieved.
[0154] In certain embodiments, the composition is administered as a single dose.A single dose of pirenzepine may also be used when pirenzepine is used in conjunction with another substance, such as an analgesic, to treat an acute condition.
[0155] In certain embodiments, pirenzepine (either by itself or in combination with other drugs) is administered in multiple doses. The number of administrations may be once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times or more per day. The dosage may be once a year, twice a year, once every six months, once every four months, once every three months, once every 60 days, once a month, once every two weeks, once a week or once every other day. In one embodiment, the drug is an analgesic. In another embodiment, pirenzepine and another therapeutic substance are administered together from about once to about 10 times per day. In another embodiment, another therapeutic substance is taken at the same time, before or after taking pirenzepine. In another embodiment, the duration of administration of pirenzepine and another therapeutic substance is less than about 7 days. In another embodiment, the duration of the combined medication is more than about 6, 10, 14, one month, two months, six months or one year. In some cases, the duration of the combined administration is as needed, for example, the administration of chronic or degenerative complications.
[0156] The administration of the composition can be continued for a desired time. In certain embodiments, the composition can be continuously administered for more than 1, 2, 3, 4, 5, 6, 7, 14 or 28 days. In certain embodiments, the composition of the present disclosure can be continuously administered for less than 28, 14, 7, 6, 5, 4, 3, 2 or 1 day. In certain embodiments, the composition of the present disclosure can be continuously administered for a long period of time, for example, for the treatment of chronic pain.
[0157] The dosage of the composition to be administered in the method can be determined by routine experimentation. The daily dosage can range from about 1×10 -7 The daily dosage range may depend on the form of pilampromazine, such as the ester or salt used, and / or the route of administration, as described herein. For example, for systemic administration, a typical daily dosage range is, for example, about 1-5000 mg, or about 1-3000 mg, or about 1-2000 mg, or about 1-1000 mg, or about 1-500 mg, or about 1-100 mg, or about 10-5000 mg, or about 10-3000 mg, or about 10-2000 mg, or about 10-1000 mg, or about 10-500 mg, or about 10-200 mg, or about 10-1000 mg, or about 20-2000 mg, or about 20-1500 mg, or about 20-1000 mg, or about 20- 500 mg, or about 20-100 mg, or about 50-5000 mg, or about 50-4000 mg, or about 50-3000 mg, or about 50-2000 mg, or about 50-1000 mg, or about 50-500 mg, or about 50-100 mg, about 100-5000 mg, or about 100-4000 mg, or about 100-3000 mg, or about 100-2000 mg, or about 100-1000 mg, or about 100-500 mg, or any two of the above ranges may be used each time. In certain embodiments, the daily dose of piranhafenamide is about 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 mg. In certain embodiments, the daily dose of pilanpromazine is 0.1 mg. In certain embodiments, the daily dose of pilanpromazine is 1.0 mg. In certain embodiments, the daily dose of pilanpromazine is 10 mg. In certain embodiments, the daily dose of pilanpromazine is 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg. In certain embodiments, the daily dose of pilanpromazine is 500 mg. In certain embodiments, the daily dose of pilanpromazine is 1000 mg.
[0158] A typical daily dosage range is, for example, about 1×10 -7 g to 5.0 g, or about 1 × 10 -7 g to 2.5 g, or about 1 × 10 -7 g to 1.00 g, or about 1 × 10 -7 g to 0.5 g, or about 1 × 10 -7 g to 0.25 g, or about 1 × 10 -7 g to 0.1 g, or about 1 × 10 -7 g to 0.05 g, or about 1 × 10 -7g to 0.025 g, or about 1 × 10 -7 g to 1×10 g, or about 1×10 -2-7 g to 5 × 10 g, or about 1 × 10 -3-7 g to 2.5×10 -3 grams, or about 1×10 -7 g to 1×10 -3 grams, or about 1×10 -7 g to 5×10 g, or about 1×10 -46 grams to 5.0 grams, or about 1×10 -6 g to 2.5 g, or about 1 × 10 g to 1 g, or about 1 × 10 -6-6 gram to 0.5 gram, or about 1×10 -6 grams to 0.25 grams, or about 1×10 -6 gram to 0.1 gram, or about 1×10 -6 g to 5×10 g, or about 1×10 -2-6 g to 5×10 g, or about 1×10 -2-6 g to 2.5 × 10 g, or about 1 × 10 -2-6 grams to 1×10 grams, or about 1×10 -2-6 g to 5×10 g, or about 1×10 -3-6 g to 2.5×10 -3 g, or about 1×10 -6 g to 1×10 g, or about 1×10 g to 5×10 g, or about 1×10 -3-6-4-5-5 g to 5 g, or about 1×10 g to 2.5 g, or about 1×10 g to 1 g, or about 1×10 -5-5 g to 0.5 g, or about 1 × 10 - 5 g to 0.25 g, or about 1 × 10 -5 gram to 0.1 gram, or about 1×10 -5 gram to 0.05 gram, or about 1×10 -5 g to 2.5×10 -2 grams, or about 1×10 -5 g to 1×10 -2 grams, or about 1×10 -5 g to 5×10 -3 grams, or about 1×10 -5 Grams to 2. -3-5-3-5-4 In some embodiments, the daily dose of pirenzepine is about 1×10, 1×10 -7-6 , 1×10 -5 , 1×10, 1×10g, 1×10 -4-3-21 g, 1×10 g or 1 g. In certain embodiments, the daily dose of pirenzepine is 1×10 -7In certain embodiments, the daily dose of pirenzepine is 1×10 -5 In certain embodiments, the daily dose of pirenzepine is 1×10 -3 In certain embodiments, the daily dose of pirenzepine is 1×10 -2 In certain embodiments, a single dose range is about 1×10 -7 g to 5.0 g, or about 1 × 10 -7 grams to 2.5 grams, or about 1×10 -7 gram to 1.00 gram, or about 1×10 -7 gram to 0.5 gram, or about 1×10 -7 grams to 0.25 grams, or about 1×10 -7 gram to 0.1 gram, or about 1×10 -7 gram to 0.05g, or about 1×10 -7 g to 0.025 g, or about 1 × 10 -7 g to 1×10 g, or about 1×10 -2-7 g to 5 × 10 g, or about 1 × 10 -3-7 g to 2.5 × 10 g, or about 1 × 10 -3-7 g to 1×10 g, or about 1×10 -3-7 g to 5 × 10 g, or about 1 × 10 -4-6 g to 5.0 g, or about 1 × 10 -6 g to 2.5 g, or about 1 × 10 g to 1 g, or about 1 × 10 -6-6 g to 0.5 g, or about 1 × 10 -6 g to 0.25 g, or about 1 × 10 -6 g to 0.1 g, or about 1 × 10 -6 g to 5×10 -2 g, or about 1×10 -6 g to 5×10-2 g, or about 1×10 -6 g to 2.5×10 -2 g, or about 1×10 -6 g to 1×10 -2 g, or about 1×10 -6 g to 5 × 10 g, or about 1 × 10 -3-6 g to 2.5×10 -3 g, or about 1×10 -6 g to 1×10 g, or about 1×10 -3-6 g to 5×10-4g, or about 1×10-5g to 5g, or about 1×10-5g to 2.5g, or about 1×10g to 1g, or about 1×10 -5-5 g to 0.5 g, or about 1 × 10 -5 g to 0.25 g, or about 1 × 10-5 g to 0.1 g, or about 1 × 10 -5 g to 0.05 g, or about 1 × 10 -5 g to 2.5×10 -2 g, or about 1×10 -5 g to 1×10 -2 g, or about 1×10 -5 g to 5×10 -3 g, or about 1×10 -5 g to 2.5×10 -3 g, or about 1×10 -5 g to 1×10 -3 g, or about 1×10 -5 g to 5×10 -4 g. In certain embodiments, the above single dose is repeated 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times per day.
[0159] The amount of active ingredient administered and the frequency of administration vary depending on the patient's sex, age, weight, symptoms to be treated, desired therapeutic effect, administration route and treatment period. For delivery to adults, the formulation containing the compound may vary in concentration within the following ranges, for example, from about 0.0001 to 10.0 volume percent (W / V%), about 0.005 to 10.0 volume percent (W / V%), about 0.01 to 10.0 volume percent (W / V%), about 0.05 to 10.0 volume percent (W / V%), about 0.1 to 10.0 volume percent (W / V%), about 0.5 to 10.0 volume percent (W / V%), about 1.0 to 10.0 volume percent (W / V%), about 20 to 10.0 volume percent (W / V%), about 3.0 to 10.0 volume percent (W / V%), about 4.0 to 10.0 volume percent (W / V%), or about 5.0 to 10.0 volume percent (W / V%). In one embodiment, the formulation contains about 1.0 to 10.0 volume percent (W / V%) of the compound. Another embodiment is that the formulation contains about 0.01 to 10.0 volume percent (W / V%) of the compound. Another embodiment is that the formulation contains about 5.0 to 10.0 volume percent (W / V%) of the compound. Administration can be several times a day, once to ten times, once to four times, or once per eye.
[0160] When used in the above compositions, a therapeutically effective amount of the drug may be used in pure drug form, or, where such form exists, in the form of a pharmaceutically acceptable salt, ester or original drug.
[0161] Example
[0162] The following examples illustrate the best embodiments currently known to the present disclosure. However, it should be understood that the following are merely examples or illustrations of the application of the principles of the present disclosure. Those skilled in the art can design many modified and alternative compositions, methods and systems without departing from the spirit and scope of the present disclosure. The attached claims are intended to cover such modifications and arrangements. Therefore, although the present disclosure has been specifically described above, the following examples provide further details related to what are currently considered to be the most practical and preferred embodiments of the present disclosure.
[0163] Example 1
[0164] The materials used to prepare the topical sensitizing formulations described herein can be made by known methods or can be purchased commercially. Variants known to those of ordinary skill in the art can also be used, but are not mentioned in more detail. Based on the literature and this disclosure, a skilled artisan is fully capable of preparing the formulations of the present application.
[0165] The dosage ranges are "broad" and "narrow" according to representative topical preparations as shown in Tables 1 and 2 below.
[0166] Table 1
[0167]
[0168]
[0169] Table 2
[0170]
[0171] The use of the topical solution described in Example 1 produced the following effects on the subjects: Example 2
[0172] Subject 1 was a 44-year-old Asian man who had suffered from intermittent attacks of Guillain-Barre Syndrome (GBS) for several years, primarily affecting his mobility. For 15 years, he had found himself becoming less sensitive during sex, with delayed ejaculation, with an average ejaculation time of 40-50 minutes. After applying a 4% pilanzepine formulation (as described in Example 1) daily to the entire penis, including the glans penis (glans), shaft of the penis, and scrotum, for 2 weeks, the subject found that the time between ejaculations had shortened to an average of 30 minutes. His orgasms were significantly more intense.
[0173] Example 3
[0174] Subject 2 was a 68 year old male who applied the topical formulation described in Example 1 to the glans penis (glans) and shaft of the penis every evening for 8 weeks. After two weeks, the subject noticed a significant qualitative improvement in the positive sensations during intercourse. The subject did not perceive a decrease in sensitivity, but after 3 weeks of treatment, the subject noticed a significant improvement in sensitivity and intensity, rapidity, urgency, and duration of response over baseline stimulation levels. No negative side effects were noted, and sensation continued to improve after 4 weeks. The subject stated that he did not realize how much sensation he had lost until the sensation returned. The subject had been using 10 mg of tadalafil prior to intercourse and had reduced the dose to 5 mg due to improvements in sensitivity, duration, and hardness.
[0175] Example 4
[0176] Subject 3 is a 49 year old non-diabetic Asian male who was in good health but had difficulty ejaculating for approximately 3 years, with the condition gradually getting worse. Subject 3 used the provided topical medication inconsistently but on average once a week for 3 months. During that time, the subject's ability to orgasm has improved tremendously. Since starting treatment, there has not been a single instance where the subject has been unable to orgasm. Subject 3 reported an increase in the number of awakenings to morning erections and increased sexual sensitivity.
[0177] Example 5
[0178] Subject 4 is a 61-year-old Caucasian male who was diagnosed with type 2 diabetes in July 2010. The subject reported having had a diminished sexual response over the years and had occasionally used Cialis to treat function, but this treatment was discontinued due to side effects. The subject began applying pirenzepine topically to the penis and after two days, had an increase in sexual response and function. Subject 4 reported that he had regular nocturnal erections within three days of taking the medication and typically used the medication twice a week. The subject had noticeable sensation after applying it around the scrotum where the penis is located. The subject reported an improvement in the ability to have an erection and penetrative intercourse. Ejaculation was similar to what the patient experienced with Cialis, but without the headache.
[0179] In the above examples, we note that various skin contact areas, analgesic system contact times, methods of treating specific conditions, etc. are for illustrative purposes only. Therefore, although the method and composition have been described with reference to certain embodiments, it will be apparent to those skilled in the art that various modifications, changes, omissions and substitutions can be made without departing from the spirit of the present disclosure.
Claims
1. A method for improving sexual sensory disturbance in a subject, comprising applying an effective amount of a composition on the subject's anal genitalia, wherein the composition comprises a therapeutically effective amount of pirenzepine or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the method comprises improving anogenital sensitivity in the subject.
3. The method of claim 1 or 2, wherein the method comprises increasing anogenital sensitivity of the subject.
4. The method of claim 1 or 2, wherein the method comprises reducing anogenital sensitivity of the subject.
5. The method according to any one of claims 1 to 4, wherein the method comprises reducing anogenital pain.
6. The method of any one of claims 1 to 5, wherein the method reverses, prevents or alleviates sexual dysfunction symptoms.
7. The method of any one of claims 1 to 6, wherein the composition is applied to the anogenital skin.
8. The method according to any one of claims 1 to 7, wherein the subject is a male.
9. The method according to any one of claims 1 to 8, wherein the composition is applied to the penis and / or anus.
10. The method according to any one of claims 1 to 7, wherein the subject is a female.
11. A method according to any one of claims 1 to 7 or 9 to 10, wherein the composition is applied to the external genitalia, cervix, vagina, vulva, labia, vaginal introitus, clitoris, urethral opening, urethral folds, vulvar vestibule, perineum and / or anus.
12. The method according to any one of claims 1 to 11, wherein the composition comprises pirenzepine or a pharmaceutically acceptable salt at a concentration of about 1% to 15% by weight.
13. The method according to any one of claims 1 to 12, wherein the composition comprises pirenzepine or a pharmaceutically acceptable salt at a concentration of about 1% to 6% by weight.
14. The method of any one of claims 1 to 13, wherein the composition is formulated for topical, transdermal, or transmucosal administration.
15. The method of any one of claims 1 to 14, wherein the composition is a gel, cream, lotion, solution, suspension, emulsion, ointment, powder, crystals, spray, foam, salves, pastes, plasters, paints, bioadhesives, suppositories, tampons, body wipes, wound dressings, skin patches, genital pads, or transdermal patches.
